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1. INTRODUCTION
1.1 ORAL DRUG DELIVERY SYSTEM
(Chein Y.W., 1995, Robinson J.R., et al., 2005)
The term drug delivery covers a very broad range of techniques used to get
therapeutic agents into the human body. The limitation of the most obvious and trusted drug
delivery techniques, those of the ingested tablet and of the intravenous (IV)/ subcutaneous
(SC)/ intramuscular (IM) injections, have been recognized for some time now. The former
delivers drug into the blood only through the hepatic system, and hence the amount in the
blood stream may be much lower than the amount formulated into the tablet (ie; it has low
bioavailability); furthermore, liver damage is an unfortunate side effect of many soluble
tabletted drugs. The injection mode of delivery can be used to deliver any size of drug
molecule and is versatile in this regard, but it suffers from the obvious.
Solid dosage forms are the most popular category of pharmaceutical formulations. They
are in sense convenience dosage forms and in comparison to the liquid formulations, their
stability is of a very high order.
Oral drug delivery has been one of the most convenient and widely accepted routes of
delivery for most therapeutic agents. Indeed oral administration improves patient’s quality of
life because it is practical and prevents intravenous drawbacks (catheter infection; thrombosis
and extravasations) (Lagarce et al; 2011). However, limitations in the physical-chemical
properties of the drug sometimes prevent a successful therapeutic outcome. Specifically
problems of poor solubility and chemical stability in the gastrointestinal tract, poor
permeability and sensitivity to metabolism are often causes that result in the rejection of
potential drug candidates as commercial products.
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Based on the desired therapeutic objectives, the Oral DDS may be assorted
into different categories
 Immediate release DDS
 Delayed release DDS
 Controlled release DDS
 Sustained release DDS
 Immediate release drug delivery system
Immediate release drug delivery system is also conventional type of drug delivery
system and it is defined as immediate release of drug without any special rate controlling
features such as special coatings and other techniques.
These preparations are primarily intended to achieve faster onset of action for drugs
such as analgesics, antipyretics and coronary vasodilators. Other advantages include enhanced
oral bioavailability through transmucosal delivery and pregastric absorption, convenience
drug administration to dysphasic patients, especially the elderly and bedridden and new
business opportunities. Conventional IR formulations include fast disintegrating tablets and
granules that use effervescent mixtures, such as sodium carbonate (or sodium bicarbonate)
and citric acid (or tartaric acid), and superdisintegrants such as sodium starch glycolate,
croscarmellose sodium and crospovidone.
Immediate onset of action is required than conventional therapy. To overcome these
drawbacks, immediate release dosage form has emerged as alternative dosage form. There are
novel types of dosage forms that act very quickly after administration. The basic approach
used in development of pellets is the use of superdisintegrants like croscarmellose sodium
(CMC), sodium starch glycolate, crospovidone etc., which provide instantaneous
disintegration after administration.
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 Delayed release drug delivery system
The design of such system involves release of drugs only at a specific site in the
gastrointestinal tract. The drugs contained in such a system are those that are
i. Destroyed in the stomach or by intestinal enzymes.
ii. Known to cause gastric distress.
iii. Absorbed from a specific intestinal site or
iv. Meant to exert local effect at a specific gastro intestinal site.
The two types of delayed release systems are:
I. Intestinal release systems: A drug may be enteric coated for intestinal release of
several known reasons such as to prevent gastric irritation, prevent destabilization in gastric
pH etc.
II. Colonic release systems: Drugs are poorly absorbed through colon but may be
delivered to such a site for two reasons;
a. Local action in the treatment of ulcerative colitis and
b. Systemic absorption of protein and peptide drugs.
 Controlled release drug delivery system
Controlled drug delivery is delivery of drug at a rate or at a location determined by
needs of body or disease state over a specified period of time.
Advantages:
1. Improved patience compliance and convience due to less frequent drug administration.
2. Reduction in fluctuation in steady state and therefore better control of disease
conditions and reduced intensity of local and systemic side effect.
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3. Increased safety margin of high potency drugs due to better control of plasma levels.
4. Reduction in health care costs through improved therapy, shorter treatment period, less
frequency of dosing and reduction in personnel time to dispense, administer and monitor
patients.
Disadvantages:
1. Poor in-vitro – in-vivo correlations.
2. Possibility of dose dumping  due to food, physiologic formulation variables or
chewing or grinding of oral formulation by the patient and thus increased risk of toxicity.
3. Retrieval of drug is difficult in concentration of toxicity, poisoning or hypersensitivity
reaction.
 Sustained release drug delivery system
The aim of any drug delivery system is to provide therapeutic amount of drug to
appropriate site in the body to achieve immediate therapeutic response and to maintain the
desired drug concentration.
In the recent years sustained release (SR) dosage forms continue to draw attention in the
research for improved patient compliance and decreased incidence of adverse drug reactions.
Sustained release, sustained action, prolonged action, extended action are the terms used
to identify drug delivery system that are designed to achieve a prolonged therapeutic effect
by continuously releasing medication over an extended period of time after administration of
a single dose.
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Advantages:
1. Improvement of patient compliance because of decreased frequency of dosage.
2. Reduction in adverse effects, this is because of the nature of its release kinetics, a
sustained release formulation should be able to use less total drug over the time course of
therapy, than conventional preparation.
3. Avoidance of costly interventions such as laboratory services.
4. Optimization of duration of action of drug.
5. Controlling the site release.
Disadvantages:
1. Increased variability among dosage units.
2. Stability problems.
3. Increased cost per unit dose.
4. More rapid development of tolerance.
5. Need of additional patient education and counseling.
TIME
Figure: 1.1. Plasma drug concentration profiles for conventional, sustained, zero order
controlled release formulations.
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1.2. MULTI PARTICULATE DRUG DELIVERY SYSTEM
(Kammali Lavanya., et al., 2011, Parag A. Kulkarni., et al., 2010)
Oral drug administration has been one of the most convenient and widely accepted
routes of delivery for most therapeutic agents. Traditionally, oral dosage forms are classified
as single unit and multiple unit dosage forms. Multi particulate dosage forms are receiving an
immense attention as alternative drug delivery system for oral drug delivery even though
single unit dosage forms have been widely used for decades. The most commonly used
pharmaceutical solid dosage forms today include, granules, pellets, tablets and capsules, out
of which tablets being the most popular dosage form, accounting for 70% of all ethical
pharmaceutical preparations produced. But soon it was sensed that some of the formulating
and clinical problems (free flowing property, dose dumping, dysphasia, etc) comes along with
the single dose formulations. This lead to the dividing of monolithic dosage forms into
multiples.
Multi particulate dosage forms are pharmaceutical formulations in which the active
substance is present as a number of small independent subunits with diameter of 0.05-2.00
mm. To deliver the recommended total dose, these subunits are filled into a capsule or
compressed into a tablet. They provide many advantages over single unit systems because of
their small size. Multi particulates are less dependent on gastric emptying, resulting in less
inter and intra–subject variability in gastrointestinal transit time. They are also better
distributed and less likely to cause local irritation.
Recently much emphasis is being laid on the development of multi particulate dosage
forms in preference to single unit systems because of their potential benefits such as increased
bioavailability, reduced risk of local irritation and predictable gastric emptying.
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MUDFs are formulated as granules, pellets or mini tablets. These MUDFs, can either be
filled into hard capsules or compacted into bigger tablets or can be dispensed in a dose
pouches or pack lets.
1.2.1. TYPES OF MPDDS (www.ordonearresearchlibrary.org)
 Drug crystals
 Irregular granules
 Spheronized granules (pellets)
 Drug – loaded non- pareils (pellets)
 Mini tablets
 Melt – spray – congeal microspheres
In order to get MPDDS, drug is distributed in small particles (0.05-0.2 mm) and then
film coated to get desired drug release characteristics. Here is the account of different types of
MPDDS.
 Drug crystals
Drug Crystals, of appropriate size and shape can be coated with a modified release film
coating.
 Irregular granules
Granules used in the preparation of tablets, can be film coated. Irregular shape and
variation in particle size make it difficult to achieve uniform coating thickness around each
particle.
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 Spheronized granules (pellets)
Sphere–shaped particles simplify the coating process. The production of spheroidal
particles (pellets) is achieved by extruding the powdered mass, then cutting into small
cylindrical particles and finally spheronizing these particles to spherical shape.
 Drug -loaded non –pareils (pellets)
Spherical particles about 1mm in diameter consisting primarily of sucrose and starch
called ‘non-pareils’ which are available in the market. Following techniques can be used to
get drug loaded non pareils.
 A powder- dosing technique involving alternate dosing of powder (containing
drug substance) and binder liquid onto the surface of the non- pareils until the
required dose of the drug has been loaded.
 Spray application of drug, either suspended or dissolved in a suitable solvent
(usually water) containing a polymer (such as hydroxy propyl methyl cellulose
or polyvinyl pyrrolidine) as a binder onto the surface of the non-pareils.
 Mini tablets
Many of the other types of multi particulates described suffer from two potential batch
wise drawbacks, namely:
 Variation in particle size distribution.
 Variation in particle shape and surface roughness.
Such variability can result in variable coating thickness and thus product performance.
This problem can be overcome by using mini compressed tablets (size range of 1-2 mm)
produced using modification of traditional tabletting processes.
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 Melt-spray-congeal microspheres
Spherical, smooth, 50-µm to 300-µm particles, typically with embedded API, can be
produced by a continuous spinning disk process.
The current review focuses on the pelletized form of multiple units, they are prepared
by process called Pelletization which is referred to as a size enlargement process and the final
product obtained is called pellets.
1.3. PELLETIZATION (Puniya Supriya., 2012)
Definition
Pellets are described to be produced systematically, as geometrically defined
agglomerate obtained from diverse starting materials using different processing conditions.
They are free-flowing, spherical or semi-spherical solid units with a size range of about 0.5 -
1.5 mm and that are intended mostly for oral administration.
Ideal properties of the pellets
 Spherical shape and smooth surface.
 The particle size of pellets should be in range of 600-1000μm.
 The quantity of the active ingredient in pellets should be maximum in order to
maintain size of pellet.
1.3.1. ADVANTAGES OF PELLETS (Patel H., 2010)
In many cases the main reason for the use of pellets in the manufacture of products with
controlled release properties. However there are reasons to believe that these multiple unit
dosage forms in any case can offer a superior therapeutic effect even when modified release is
not the primary objective.
1. Improved appearance of the product which is having fine pharmaceutical elegance.
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2. Pelletization offers flexibility into the dosage form design and development.
3. Pellets improve the flow properties in formulation development.
4. They flow freely and are easy to pack without significant difficulties (resulting in
uniform and reproducible fill weight of capsules).
5. Pellets are less susceptible to dose dumping.
6. It reduces accumulation of drugs especially proven advantageous in the case of
irritating drugs.
7. It improves safety and efficacy of a drug.
8. Pelletization is a convenient way to manage the separation of incompatible drugs.
9. Pellets offer reduced variation in gastric emptying rate and intestinal transit time.
1.3.2. DISADVANTAGES OF PELLETS
1. Dosing by volume rather than number and splitting into single dose units as required.
2. Involves capsule filling which can increase the costs or tabletting which destroy film
coatings on the pellets.
3. The size of pellets varies from formulation to formulation but usually lies between 1 to
2 mm.
1.3.3. THEORY OF PELLET FORMATION AND GROWTH
(Kammali Lavanya., et al., 2011)
Before selection and optimization of any Pelletization /granulation process, it is
important to understand the fundamental mechanisms of pellet formation and growth.
Different theories have been postulated related to the mechanism of formation and growth of
pellets. Some of these theories are derived from experimental results while others are derived
by visual observations. Out of these hypothetical theories the most convincing classification is
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of Pelletization process, involves three consecutive regions: nucleation, transition and ball
growth. However, based on the experiments on the mechanism of pellet formation and
growth, the following steps were proposed: nucleation, coalescence, layering and abrasion
transfer.
Figure: 1.2. Pellet Growth Mechanism.
The fines and the fragments produced through size reduction are taken up by larger
pellets. Production of fines and subsequent coalescence and layering continues until the
number of collisions declines rapidly, thereby leading to a reduction in the rate of growth of
the pellets. At this point the third phase, the ball growth region, is reached. The main
mechanism in the ball growth phase is the abrasion transfer which involves the transfer of
materials from one granule formed to another without any preference in either direction. This
phase does not result in any change in the total number or mass of the particles. However, the
particles undergo a continuous change in their size as long as the conditions that lead to the
transfer of material exist.
A.Nucleation
B. Coalescence
C. Layering
D. Abrasion
transfer
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1.3.4. METHODS OF PREPARING PELLETS
Compaction and drug layering are the most widely used pelletization techniques in
Pharmaceutical industry. Of the compaction techniques, extrusion and spheronization is the
most popular method. Recently, however, melt pelletization has been used frequently in
making compaction pellets using a different type of equipment, e.g. a high-shear mixer. Other
pelletization methods such as globulation, balling and Compression are also used in
development of pharmaceutical pellets although in a limited scale.
 Drug  layering
Powder layering involves the deposition of successive layers of dry powders of drugs
and excipients on preformed nuclei or cores with the help of binding liquids. As powder
layering involves simultaneous application of binding agents and dry powders, hence it
requires specialized equipments like spheronizer. The primary requirement in this process is
that the product container should be solid walls with no perforation to avoid powder lose
beneath the product chute before the powder is picked off by the wet mass of pellets that is
being layered.
Spraying                       Wetting distribution Layer formation                      Pellet
Figure: 1.3. Drug layering method by using solution.
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 Suspension  layering
Suspension layering involves the deposition of successive layers of suspensions of
drug substances and binder over the starter/non-pareil seeds, which is an inert material or
crystals/granules of the same drug. In fact the coating process involved in general is
applicable to suspension layering technology. Consequently conventional coating pans,
fluidized beds, centrifugal granulators, wurster coaters have been used successively to
manufacture pellets by this method. The efficiency of the process and the quality of the pellets
produced are in part related to the type of equipment used.
Spraying Rolling Solidifying Layer Formation Pellet
Figure: 1.4. Drug layering method by using suspension.
 Pelletization by extrusion and spheronization
The process involves first making the extrudes from the powder material and then
converting the extrudes into beads using the spheronizer. The powder material could be any
kind of powder (drug powder, ayurvedic powder, food ingredient powder, detergent powder,
nuclear powder etc). Beads are fine as 0.6mm can be made.
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Figure: 1.5. Extrusion and spheronization process
 Direct pelletization
Sample material is blended and solvent or binder system is added to it. The material bed
is then subjected to a centrifugal motion. The centrifugal forces act on the material in this
process resulting in the formation agglomerates, which get rounded up into uniform sized
dense pellets. The size, density and shape of the pellets formed are influenced by the speed of
rotation. The moist pellets formed are then dried up in the fluid bed. Organic solvents can also
be used if required.
Spraying Rolling Drying Pellet
Figure: 1.6. Direct pelletization process for preparation of pellets.
 OTHER PELLETIZATION METHODS
Other pelletization methods such as globulation, cryopelletization, balling compression
are also used, although a limited scale in the preparation of pharmaceutical pellets.
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 Globulation or droplet formation consists of two related processes, spray drying
and spray congealing.
 Spray drying
It is the process in which drugs in the suspension or solution without excipients are
sprayed in to a hot stream to produce dry and more spherical particles. This process is
commonly used for improving the dissolution rates; hence bioavailability of poorly soluble
drugs.
 Spray congealing
It is the process in which a drug is allowed to melt, disperse or dissolve in hot melts
of gums, waxes or fatty acids, and is sprayed into an air chamber where the temperature is
kept below the melting point of the formulation components, to produce spherical congealed
pellets. Both immediate and controlled release pellets can be prepared in this process
depending on the physiochemical properties of the ingredients and other formulation
variables.
 Cryopelletization
It is a process in which the liquid formulation is converted in to solid spherical
particles or pellets in the presence of liquid nitrogen as fixing medium. The shape depends up
on the distance the droplet travel before contacting liquid nitrogen.
 Compression
It is one type of compaction technique for preparing pellets. Compacting mixtures
or blends of active ingredients and excipients under pressure prepare pellets of definite sizes
and shapes. The formulation and process variables controlling the quality of pellets prepared
are similar to those used in tablets manufacturing.
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 Balling
It is the pelletization process in which pellets are formed by a continuous rolling
and tumbling motion in pans, discs, drums or mixtures. The process consists of conversion of
finely divided particles in to spherical particles upon the addition of appropriate amounts of
liquid.
 EXCIPIENTS FOR PELLETS
Formulation aids or excipients are added to pharmaceutical dosage forms mainly to
produce satisfactory delivery of the drug to the intended site, to impart favourable
characteristics to the dosage form and to facilitate the manufacture of the product. Since
pellets are intended to be administered orally, the excipients used in the pellet dosage forms
are typically the same as those used in tablet or capsule formulations.
Excipients, Disintegrants, Surfactants, pH adjusters, Separating agents, Spheronization
enhancers, Glidants and release modifiers etc. some examples of such excipients are given in
Table: 1.1. Examples of Excipients commonly used for pellets
Filler MCC, starch, sucrose, lactose, mannitol
Binder Gelatin, HPC, HPMC, MC, PVP, sucrose,
starch
Lubricant Calcium stearate, glycerin, PEG, Mg. stearate
Separating agent Kaolin, talc, silicon dioxide
Disintegrant Alginates, croscarmellose sodium
pH adjuster Citrate, phosphate, meglumine.
Surfactant Polysorbate, SLS
Spheronization enhancer MCC , sodium CMC
Glidant Talc, starch, Mg stearate.
Release modifier Ethyl cellulose, carnauba wax, shellac.
Atorvastatin Calcium Immediate Release Pellets Introduction
Page 17
Adhiparasakthi college of Pharmacy, Melmaruvathur.
1.3.5. PELLET COATING PROCESS
The coating process for pellets is carried out primarily in order to modify the release of
the drug from the pelletized drug delivery systems. Following are the some of the coating
equipments used for this purpose Most of the coating processes use one of three general types
of equipments.
 The standard Coating pan
 The Perforated Coating pan
 The Fluidized bed coater
 Standard coating pan
The standard coating pan system consists of a circular metal pan mounted somewhat
angularly on a stand, the pan is rotated on its horizontal axis by a motor, the hot air is directed
into the pan and onto the bed surface, and is exhausted by means of ducts positioned through
the front of the pan .Coating solutions are applied by spraying the material on the bed surface.
 Perforated coating pan
Neocota is an automatic coating system for tablets and pellets.Neocota is a completely
updated automatic coating system having a batch capacity of 500 g to 1 kg. This model
efficiently carries out the following operations: Aqueous film coating of tablets/pellets; Non-
aqueous organic solvent based film coating of tablets/pellets; and enteric film coating of
tablets/pellets.
The basic units of the system are: Coating pan has perforations along its cylindrical
portion. It is driven by a variable speed drive with a flame-proof motor. Supply of hot air and
exhaust of drying air are arranged to facilitate the coating system through stainless steel
platinums positioned on both sides of the perforated coating pan. The pan is enclosed in a
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cylindrical air tight housing provided with a suitable door and front glass window. This
housing of pan with drive is a stainless steel cabinet acommodating the gearbox, AC variable
drive, power panel, hot air unit, ex-haust unit and an air fitter.
Liquid spray system is complete with stainless steel liquid storage vessel, variable flow-
rate liquid dosing pump, automatic spray gun, and inter-connecting flexible hoses.
An important disadvantage of pan coater is limited process control. More recently
modified pan coaters have been developed, which resolve many of the drawbacks related to
the old system.
The problems of drug layering pelletization by conventional pan coaters had led to the
development of two types of rotary granulators.
 Fluidized –bed granulators
 Centrifugal granulators.
These devices offer many advantages including lower manufacturing costs, flexibility of
operation and ease of automation.
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Figure: 1.7.Conventional pan coater
 THE FLUIDIZED BED COATER
The Fluid Bed Technology offers a very efficient coating technique. The major
advantage of the Fluid Bed Systems is that it is as per GMP standards it is a closed system.
The second advantage of the Fluid Bed Systems is that not only coating but granulation and
pellet formation is also possible in the same machine.  Fluidized bed coating is a process that
takes place inside a fluidized bed whereby a coat is introduced to cover the intended object in
order to protect it or modify its behaviour. Particulate coating is a form of fluidized bed
coating involving the coating of solid particles inside the bed. In the process, a layer is
deposited onto the surface of fluidized solid particles by spraying with a solution of the
coating material. The fluidizing gas is also use to dry the deposited solution to form a coat on
the surface of the particle. There is considerable diversity in methods of using fluidized bed
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technology. For e.g. liquids can be applied to fluidized particles in a variety of ways,
including top, bottom and tangential spraying. For a given product, each method can offer
markedly different finished product characteristics. Fluidized beds are used for coating
because of their high energy and mass transfer. Fluidized beds for film coating can be divided
into three groups.
 Top -spray
 Bottom –spray equipments
 Tangential-spray
 Top spray (Wurster.D., 1953 )
The expansion chamber is lengthened to allow powder to remain fluidized longer and to
move with a higher velocity, so that agglomeration is minimized. The expansion chamber is
conically shaped to allow uniform deceleration of air stream .The filter housing is larger and
designed to shake the fines back into the bed interrupting fluidization this reduces
agglomeration tendencies.
The nozzle is positioned low in the expansion chamber so that coating material impinge
on the fluidized particle a short distance from the nozzle; this reduces droplet spray drying
and provides for longer subsequent drying of the coated particles. The top spray coater has
been used to apply aqueous and organic solvent based film coatings, controlled release
coatings.
 Bottom spray coating ( wurster process, Make-GLATT)
The wurster machine employs a cylindrical product container with a perforated plate.
Inside the container is a second cylinder (coating partition) with is raised slightly above the
perforated plate, centered in the plate below this partition is a spray nozzle used to dispense
the coating solution. The perforated plate is designed with large holes in the area under the
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coating partition and smaller holes in the remainder of the plate, except for one ring of large
holes at the perimeter. The design allows the substrate particles to be pneumatically
transported upward through the coating partition, and downward outside this partition.
Material passing through coating partition receives a layer of coating material, dries in the
expansion chamber, and falls back in a semi fluidized state. Material circulates rapidly in this
fashion and receives layer of coating material, dries in the expansion chamber, and falls back
in a semi fluidized state material circulates rapidly in this fashion and receives a layer of
coating on each pass through the coating partition. The ring of large holes on the periphery of
perforated plate prevents the accumulation of material at the container wall. It has been used
for coating small particles, pellets and tablets.
Table: 1.2. Parameters Used in Bottom Spray Equipment
Inlet temperature 38-42ºC
Product temperature 32-36ºC
Exhaust temperature 32-38ºC
Spray rate 8-12mg/min
Peristaltic pump 12-18 rpm
 Fluid bed coating
Particles smaller than approximately 2mm should be coated in fluid bed equipments,
because with decreasing particle diameter the specific surface area of a substrate increases
dramatically. Thus, the required coating weight gain is much higher than tablet coating
processes. In order to achieve acceptable process times, the high efficiency of fluid bed
compared to pan coating equipment shows clear advantages in particles coating processes.
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Shape - In order to achieve good flow properties, spherical particles with smooth
surfaces are preferred, while needle shaped particles show poor flow properties and tend to
form lumps. Another advantage of the latter is the increased risk of breakage during the
coating process, creating uncoated spaces and leading to an increased coating weight gain
.Besides crystals and pellets, granules can be used as substrates as a disadvantages. We may
have uneven surfaces and often increased abrasion compared to the shapes mentioned first,
which can also lead to increased surface areas which require higher amounts of coating.
Size- Usual particle sizes are in arrange of 0.2-1.2mm.smaller particles may have
problematic flow properties in higher scale and may tend to break if the length /diameter-ratio
is 2. Smaller particle size are required if particles are administered from sachets or
incorporated into chewable tablets. In order to avoid damage by chewing, the coated
particles should have a maximum size of 0.4mm smaller end products may given a better
mouth felling but increasing specific surface areas requires higher coating amounts.
 Tangential spray
The tangential spray method is known and used for particle coating and granulation
processes. Compared to other fluid bed coating technologies, the top spray method is
susceptible for porous film structure, especially if organic coating formulations are processed.
Bottom spraying (wurster process) is the usual method in particle coating due to a more
uniform particle movement, better film structures can be achieved compared to the top spray
method, and the required polymer weight gain for a certain function is usually lower to some
extent. A disadvantage is that in case of nozzle blockage during the coating process, the
product must be discharged before the nozzles can be cleaned. Tangential spraying system,
which is commonly fitted with a rotating bottom plate, can achieve film quantities nearly as
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good as bottom–spraying system. The rotation of the plate nicely supports product movement,
so that the required air amount is mainly used for drying process and only to a smaller degree
for the product movement.
Nozzles for the particle coating – Common spray gun are air-borne with a round
spray pattern. Some equipment is fitted with a double air supply which is used for common
atomizing air and extra microclimate air, which surrounds the spray pattern, preventing over
wetting of the product and reducing spray drying effects.
Pump system – Peristaltic pumps fitted with silicon tubing are standard. Tubing can
be selected in a wide range of internal diameters in order to keep the flow speed high and
hence to prevent sedimentation. Therefore the use of tubing with small internal diameters
recommended. Alternative pump systems include gear pumps and piston pumps.
Rotating disk granulation - Granulation techniques utilizing centrifugal fluidizing
drive has been studied only recently. These techniques have been extended to coating
operations and combined with an expansion chamber to form the rotating disk granulator and
coater fluid bed device. The basic design employs a rotating disk in the product container.
The disk can be moved up or down to create a variable slit opening between the outer
perimeter of the disk and the sidewall of the container. Air is drawn into the product container
through the slit under negative pressure. This fluidizes the material along the circumferential
surface of the product container. At the same time the disk rotates at varying speeds and
moves the product by the centrifugal force to the outer portions where it is lifted by the
fluidizing air stream into the expansion chamber. As the material decelerates, it descends to
the centre of the disk and repeats the same sequence. The fluidization pattern is often
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described as a spiralling helix or rope-like pattern around the inside of the rotor chamber.
Spray nozzles can be immersed in the bed of fluidized material and spray applied in tangential
fashion with respect to the particle flow.
Table: 1.3. Different polymers used in the pelletization process
(www.ijpsr.com)
Polymer used in
pelletization
Formulation Applications
Carbopol 974P,NF, Resin. Beads containing Weakly
basic drugs.
Slower release of the salts
of weakly basic drugs.
Crosscarmellose sodium
or sodium starch
glycolate.
Super-disintegrants in
avicel pellets.
Increase dissolution rate,
increase the pellet
micropore volume.
Eudragit RS PO and RL
PO.
Polymer (with
combination) based pellets.
Better characterization like
elastic modulus of the
pellets, surface
characteristics, sphericity.
Eudragit RL 30D, RS
30D, NE 30D.
A multiple- unit floating
drug delivery system.
Prolong the gastric
residence time and to
increase the overall
bioavailability of the
dosage form.
Gelucire. Lipidic –matrix pellets. Controlled drug release.
Methocel-E5 (HPMC) or
AMB, Eudragit L 30D-55.
Enteric coated pellets. Improved film formation
and polymer coalescence.
Microcrystalline cellulose,
Ac-Di- Sol.
Floating pellets with
bacterial antagonist.
Improving floating
property.
Microcrystalline cellulose
and hydroxy propyl
methyl cellulose.
Pellets with water insoluble
drugs in self-emulsified
form.
Controlling the drug
release from the oral
dosage forms.
Pectins or alginates. Polysaccharide gel coated
pellets.
Oral administration of
theophylline in the coated
pellets.
1.4. CAPSULES (Lachman L., et al.,1991)
Capsule is a solid oral dosage form consisting of a shell and a filling. The shell is
composed of a single sealed enclosure, or two halves that fit together and which are
sometimes sealed. Capsule shells may be made from gelatin, starch or cellulose, or suitable
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material, may be soft or hard, and are filled with solid or liquid ingredients that can be poured
are squeezed. Capsule is a shell or a container prepared from gelatin containing one or more
medicinal and/or inert substances. The gelatin capsule shell may be soft or hard depending on
their formulation.  Capsules are intended to be swallowed whole by the patient.  In instances
where patients (especially children) are unable to swallow capsules, the contents of the
capsule can be removed and added (e.g., sprinkled) on soft food immediately before ingestion.
In this case, capsules are used as a vehicle to deliver premeasured medicinal powder.  Capsule
dosage forms occupy more than 10% of the total dosage forms on the market (Augsburger,
1990).  An example is Contac 600 (GlaxoSmithKline) in which the active ingredients in the
capsule are encapsulated in hundreds of micro beads in a sustained release form (based on the
Spansule ® technology).
1.4.1. Advantages of capsules
a. Ease of swallowing.
b. Dosage accuracy/uniformity: Precise fill volume of liquid fill unit delivers a greater
degree of accuracy and consistency from capsule to-capsule and lot-to-lot.
c. Consistent manufacturing requirements: More accurate compounding, blending, and
dispensing of liquid fill facilitates manufacturing.
d. Liquid blends are more homogeneous.
e. Increase in bioavailability: Absorption and bioavailability can be enhanced by
formulating compounds in solution including solubilizers and absorption enhancers, if
necessary.
f. Water-insoluble drugs may be formulated in a soft gel.  Clinical studies have shown
enhanced absorption and bioavailability with soft gel forms.  Examples are Temazepam and
Ibuprofen.
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g. Enhanced stability and security: The tight hermetical sealing protects fill from air and
environmental contamination.  Gelatin shell can be formulated to block out ultraviolet light.
Streamlined, one-piece design is tamper-evident.
h. Pliable shell: Soft gel shell allows for custom shapes and sizes appropriate for oral,
topical, chewable and suppository delivery.
i. Portability: Encapsulated liquid dosage formulations become highly portable for
consumers/patients.
Applications
Soft gelatin capsules can be used to encapsulate a variety of liquids, such as oils,
hydrocarbons, organic acids, polyethylene glycols, and nonionic surfactants.  Some liquids
can migrate through the capsule shell, and those liquids cannot be encapsulated into the soft
gelatin capsules. These include water and low molecular weight water-soluble organic
compounds.  Soft gelatin capsules can also be used to encapsulate dry fills, such as powders,
granules, and pelletized materials.
1.5. SUPER DISINTEGRANTS (www.pharmainfo.net)
A disintegrant helps the capsule to break up into small pieces upon contact with
aqueous solution. Fast disintegration of a capsule in the oral cavity facilitates swallowing and
increases the surface area of the capsule particles, which enhances the rate of absorption of
the active ingredient to achieve the desired therapeutic effect. Every marketed pellets has a
certain level of disintegrant and it is important to investigate which and how much
disintegrant is necessary for a given pellet formulation. Disintegration starts when a small
amount of water or saliva contacts the dosage form (wetting) and penetrates the capsule by
capillary action.  Therefore, the material properties of pharmaceutical excipients and also the
pellet structure including pore size and distribution need to be considered for successful
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formulation development. Since most disintegrants swell to some extent, swelling pressure is
generally considered the main factor for pellet disintegration. Disintegrants or super
disintegrants with efficient disintegrating properties at relatively low levels can be used in the
formulation of immediate release pellets. They are generally added at a level of 1-10% (w/w
%).
Disintegration efficiency is based on the force-equivalent concept (the combined
measurement of swelling force development and amount of water absorption).Force
equivalence expresses the capability of a disintegrant to transform absorbed water into
swelling (or disintegrating) force. The optimization of pellet disintegration is commonly done
by mean of the disintegration critical concentration. Below this concentration the pellet
disintegration time is inversely proportional to the disintegrant concentration. Above the
critical concentration, the disintegration time remains approximately constant or even
increased. One of the most desirable properties of disintegrants is rapid swelling without an
accompanying viscosity increase (no gel formation), because high viscosity on the surface of
the capsule will hinder water penetration into the capsule matrix to slow disintegrants.
There are a lot of disintegrants and super disintegrants on the market and most of them
can be considered for use in IRPs. Typical examples includes crospovidone (cross linked
PVP) , Croscarmellose (cross linked cellulose), sodium starch glycolate (cross linked starch),
and low- substituted hydroxypropylcellulose. Crospovidone is a synthetic and water insoluble
cross-linked homo-polymer with the chemical structure of N-Vinyl-2-Pyrrolidone. A unique
one-step polymerization process known as “pop corn” polymerization is used to synthesize
crospovidone polymers. Cross linking chemically “entangles” the polymer chains and is a
major determinant of the product properties. This process results in a porous structure with
densely cross-linked polymers and a morphology that rapidly wicks liquid into a particle to
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enhance swelling and disintegration. Crospovidone polymers are non-ionic. So their
disintegration properties are independent of pH changes in the gastrointestinal tract.
Moreover, they do not form gels.
Ac-Di-Sol (croscarmellose sodium) is internally cross-linked sodium carboxyl methyl
cellulose. Primojel is a sodium starch glycolate produced by cross-linking and carboxyl
methylation of potato starch. Both exhibit good water uptake with high capillary action and
rapid swelling. The high swelling capacity together with high water penetration leads to fast
tablet/capsule disintegration.
Disintegrants are usually water insoluble materials that swell on contact with moisture,
therefore the addition of excess disintegrant can lead to grittiness after tablet disintegration.
The appropriate disintegrant and disintegrant quantity should be carefully investigated for a
given formulation.
The particle size distribution of Kollidon CL and Polyplasdone XL is similar. However,
bulk and tapped densities of the both are significantly different due to the smoother surface of
Kollidon CL or the porous structure of Polyplasdone XL, Kollidons CL-F and CL-SF have
lower bulk densities than that of Polyplasdone XL because of their smaller particle sizes.
Primojel has the highest bulk and tapped densities and Ac-Di-Sol is in between Kollidon CL
and Primojel. Selection of right disintegrant depends on the formulation application and
preparation procedure.
Crospovidone can work as an efficient disintegrant with fast swelling properties.
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Need for fast disintegrating pellets (Suresh Bandari., et al., 2010)
The  need  for  non-invasive  delivery  systems  continues  due  to patients  poor
acceptance  and  compliance  with  existing  delivery  regimes , limited  market  size  for  drug
companies  and drug  uses,  coupled  with  cost  of  disease  management.
The  current  needs  of  the  industry  are  improved  solubility / stability ,  biological
half-life and bioavailability enhancement of poorly absorbed drugs. Key issues facing the
biopharma industry are to improve safety (decreasing gastrointestinal side effects), improve
efficacy for organ targeting, and improved compliance via sustained release or easy to
swallow.
Developing new drug delivery technologies and utilizing them in product development
is critical for pharmaceutical companies to survive. Pharmaceutical marketing is another
reason for the increase in available fast-dissolving / disintegrating products. As a drug entity
nears the end of its patent life, it is common for pharmaceutical manufacturers to develop a
given entity in a new and improved dosage form. A new dosage form allows a manufacturer
to extend market exclusivity, while offering its patient population a more convenient dosage
form or dosing regimen. In this regard, fast-dissolving / disintegrating pellet formulations are
similar to many sustained release formulations that are now commonly available. An
extension of market exclusively , which can be provided by a fast- dissolving/ disintegrating
dosage form, leads to increased revenue , while also targeting under served and under- treated
patient populations. Although the cost to manufacture these specialized dosage forms exceeds
that of traditional tablets, this additional cost is not being passed on to the consumer.
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1.5.1. MECHANISM OF DISINTEGRANTS
The pellet breaks to primary particles by one or more of the mechanisms
 Capillary action (Wicking)
 Swelling
 Due to deformation
 Due to release of gases
 Due to disintegrating particle / particle repulsive forces
 By enzymatic action
 Capillary action (wicking)
Effective disintegrants that do not swell are believed to impart their disintegrating
action through porosity and capillary action. Capsule porosity provides way for the
penetration of fluid into capsule. The disintegrant particles (with cohesiveness and
compressibility) themselves act to enhance porosity and provide these capillaries into the
tablet. Liquid is drawn up or leak into these ways by capillary action and rupture the inter-
particulate bonds causing the capsule to break into small particles.
 Swelling
Not all disintegrants swell in contact with water swelling is believed to be a mechanism
in which; certain disintegrating agents (like starch) impart their disintegrating effect. By
swelling on contact with water the adhesiveness of other ingredients in a capsule is overcome
causing the tablet to disintegrate.
Particles swell and break up the matrix from within swelling sets up localized stress
spreads throughout the matrix.
Atorvastatin Calcium Immediate Release Pellets Introduction
Page 31
Adhiparasakthi college of Pharmacy, Melmaruvathur.
Water is pulled into pores by disintegrants and reduces the physical bonding between
Particles.
Figure: 1.8.Mechanism of capsule disintegration by wicking and swelling
 Due to deformation
Starch grains are generally thought to be “elastic” in nature that is the grains that are
deformed under pressure will return to their original shape when that pressure is removed.
But, with the compression force involved in tabletting, these grains are permanently deformed
and are said to be “Energy Rich” with these energy being released upon exposure to water i.e.,
the ability for starch to swell is higher in “Energy Rich starch” grains than in starch grains that
have not been deformed under pressure. It is believed that no single mechanism is responsible
for the action of most disintegrants. But rather, it is more likely the result of inter-
relationships between these major mechanisms.
Figure: 1.9. Mechanism of capsule disintegration by deformation
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Particles swell to pre compression size and break up the matrix.
 Due to release of gases
Carbon dioxide released within tablets on wetting due to interaction between
bicarbonate and carbonate with citric acid or tartaric acid. The tablet disintegrates due to
generation of pressure within the tablet. This effervescent mixture is used when we needs to
formulate very rapidly dissolving tablets or fast disintegrating tablet.
 Due to disintegrating particle/ Particle repulsive forces
Another mechanism of disintegration attempts to explain the swelling of capsule made
with “non-swellable disintegrants”. Guyot- Hermann has proposed a particle repulsion theory
based on the observation of non swelling particles also cause disintegration of pellets.
 By Enzymatic Reaction
Table: 1.4. Enzymes presents in the body as disintegrants
ENZYMES BINDER
Amylase Starch
Protease Gelatine
Cellulose cellulose and its derivatives
Invertase Sucrose
1.6. ANTI LIPIDEMIC DRUGS
Lipids (Anne Marie Helmenstine., 2005)
The term 'lipid' was first used by the German biochemist Bloor in 1943 for a major class
of tissue components and foodstuffs.
A lipid is a fat-soluble molecule. To put it another way, lipids are insoluble in water but
soluble in at least one organic solvent. The other major classes of organic compounds (nucleic
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acids, proteins, and carbohydrates) are much more soluble in water than in an organic solvent.
Lipids do not share a common molecule structure.
Lipids are bio molecules which are soluble in organic non-polar solvents. Consequently,
fats and lipids are insoluble in water. Glycerides and waxes form a sub-group of compounds
which have an ester as the major functional group and including waxes, triglycerides, and
phospholipids. Lipids without ester functional groups including steroids, fatty acids, soaps,
sphingolipids and prostaglandins.
Figure: 1.10 Life Cycle of Cholesterol
Definition of lipids (James Richard Fromm., 1997)
A lipid is defined as a water-insoluble bio molecule which has a high solubility in
nonpolar organic solvents such as chloroform. The simplest lipids are the fats, which are tri
esters made up of one glycerol and three fatty acids.
The term fats is also used as a general synonym for lipids, so the more precise terms
triacylglycerols or triglycerides are preferable for the simplest lipids. Triacylglycerols are
used primarily for energy storage in animals. More complex lipids, the phospholipids,
glycolipids, and cholesterol, are the major constituents of biological cell membranes.
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Figure: 1.11. Types of Lipids.
Examples of common lipids (Charles E and Ophardt ., 2003)
Examples of common lipids include
 Butter
 Vegetable oil
 Cholesterol and other steroids
 Waxes
 Phospholipids
 Fat-soluble vitamins
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Classification of lipids (Charles E and Ophardt., 2003)
Table: 1.5. Classification of lipids
1.6.1. Lipid structure
Although there is no single common structure for lipids, the most commonly occurring
class of lipids are triglycerides, which are fats and oils. Triglycerides have a glycerol
backbone bonded to three fatty acids. If the three fatty acids are identical then the triglyceride
is termed a simple triglyceride. Otherwise, the triglyceride is called a mixed triglyceride.
The second most abundant class of lipids are the phospholipids, which are found in
animal and plant cell membranes. Phospholipids also contain glycerol and fatty acids, plus the
contain phosphoric acid and a low-molecular-weight alcohol. Common phospholipids include
lecithins and cephalins.
The most important lipids present in blood plasma include fatty acids, triglycerides,
cholesterol, phospholipids and steroid hormones.
LIPID CLASSIFICATION AND EXAMPLES
Fatty Acids Glycerides
Saturated Fatty Acids Steroids
Unsaturated Fatty Acids Lipoproteins
Soap (salt of fatty acid) Triglycerides
Prostaglandins Phosphoglycerides
Non glyceride Lipids
-
Waxes
-
Sphingolipids
-
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 Triglycerides, Cholesterol and Phospholipids
Triglycerides are esters of fatty acids (e.g., stearic C-18 or palmitic C-16) and glycerols.
Most of fatty acids are saturated, whereas nonsaturated fatty acids play an important role as
prostaglandin precursors and in the process of cholesterol esterification.
Cholesterol also is a cellular membrane element and precursor of steroid hormones and
biliary acids.
Phospholipids are structurally similar to triglycerides, except that one minor acid is
substituted by a phosphorous group and nitrogen base.
 Functions of lipids (Charles E and Ophardt., 2003)
 Fats and lipids are important because they serve as energy source, as well as storage
for energy in the form of fat cells.
 Lipids have a major cellular function as structural components in cell membranes.
These membranes in association with carbohydrates and proteins regulate the flow of water,
ions, and other molecules into and out of the cells.
 Hormone steroids and prostaglandins are chemical messengers between body tissues.
 Vitamins A, D, E, and K are lipid soluble and regulate critical biological processes.
Other lipids add in vitamin absorption and transportation.
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Figure: 1.12. Lipid function and metabolism
Lipids act as a shock absorber to protect vital organs and insulate the body from
temperature.
 Energy storage, mobilization, and utilization
 Protection of organs
 Insulation
 Storage of vitamins-ADEK
 Hormone production.
Lipid metabolism impairments (Charles E and Ophardt., 2003)
Assessment of lipid metabolism impairments is based on plasma concentrations of
cholesterol and triglycerides, and on data obtained by lipoprotein electrophoresis. Therefore, a
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fasting period of 14-16 hours is required before blood sampling for analysis. Disorders due to
lipid metabolism impairments are associated with a high risk of atherosclerosis.
Figure: 1.13. Lipid metabolism impairments
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Table: 1.6. Anti lipidemic drugs (Witiak D.T., et al., 1991)
1.7. HMG-CoA REDUCTASE INHIBITORS (STATINS)
In 1980s, this type was the most efficacious and best tolerated hypolipidaemic drugs.
They competitively inhibit conversion of 3-Hydroxy-3-methyl glutaryl coenzyme A (HMG-
CoA) to mevalonate (rate limiting step in CH synthesis) by the enzyme HMG-CoA reductase.
Therapeutic doses reduce CH synthesis by 2-50%. This results in compensatory increase in
LDL receptor expression on liver cells―›increased receptor mediated uptake and catabolism
of IDL and LDL. Over long term, feedback induction of HMG-CoA reductase tends to
S.NO CLASSIFICATION NAME OF THE DRUGS
1. HMG - CoA reductase inhibitors (Statins)  Lovastatin
 Simvastatin
 Pravastatin
 Atorvastatin
 Rosuvastatin
 Lovastatin
2. Bile and sequestrants (Resins)  Cholestyramine
 Colestipol
3. Active lipoprotein lipase (Fibric acid
derivaties)
 Clofibrate
 Gemfibrozil
 Bezafibrate
 Fenofibrate
4. Inhibit lipolysis and triglyceride synthesis  Nicotinic acid
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increase CH synthesis, but a steady-state is finally attained with a dose-dependent lowering of
LDL-CH levels
The daily dose for lowering LDL-CH by 30-35% is lovastatin 40mg, provastatin 40mg,
simvastatin 20mg, Atorvastatin 10mg, Rosuvastatin 5mg. Moreover, maximum recommended
doses simvastatin, Atorvastatin and Rosuvastatin can reduce LDL-CH by upto 45-55%,
while the ceiling effect of lovastatin and Pravastatin is 35-40% LDL-CH reduction.
Table: 1.7. Mechanism of action and pattern of lipid lowering effect of important
hypolipidaemic drug (Michael E. Maragoudakis., 1970)
S.NO CLASSIFICATION NAME OF THE
DRUGS
DAILY
DOSAGE
MECHANISM OF ACTION
1. HMG-
CoAreductaseinhibitors
(Statins).
Lovastatin (10-80mg)
Simvastatin (5-40mg)
Pravastatin  Decreased CH synthesis by
inhibition of rate limiting
HMG-CoA reductaseAtorvastatin (10-80mg)
Rosuvastatin (5-20mg)
Lovastatin (10-80mg)
2. Bile and
sequestrants(Resins).
Cholestyramine (4-16 mg)  Decreased bile acid
absorption,
 Increased hepatic conversion
of CH to bile acids
 Increased LDL receptors on
hepatocytes
Colestipol (5-30 mg)
3. Active lipoprotein lipase
(Fibric acid derivatives).
Clofibrate
 Increased Activity of
lipoprotein lipase
 Decreased release of fatty
acids from adipose tissue
Gemfibrozil (1200 mg)
Bezafibrate (600 mg)
Fenofibrate (200 mg)
HMG-CoA reductase pathway, which is blocked by statins via inhibiting the rate
limiting enzyme HMG-CoA reductase
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Figure: 1.14 HMG-CoA reductase pathways, which is blocked by statins via inhibiting
the rate limiting enzyme.
The more effacious statins (simvastatin, atorvastatin, rosuvastatin) given at their high
doses effectively reduce (by 25% to 35%). Because HMG-CoA reductase activity is
maximum at midnight, all statins are administered at bed time to obtain maximum
effectiveness. But, this is not necessary for atorvastatin and rosuvastatin, which have long
plasma t1/2.
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1.7.1. Other statins drugs (Richard N., Fogoros M.D., 2010)
 Lovastatin
It is the first clinically used statin; is lipophilic and given orally in the precursor lactone
form.
Lovastatin 40mg.
Systematic (IUPAC) name
1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-
1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate
Absorption – incomplete
Metabolism – bile
t1/2 - short (1-4 hours)
Dose – 10 to 40 mg
 Simvastatin
It is a hypolipidemic drug used to control elevated cholesterol. Simvastatin is a member
of the statin class of pharmaceuticals, is a synthetic derivate of a fermentation product of
Aspergillusterreus.
Systematic (IUPAC) name
(1S, 3R, 7S, 8S, 8aR)-8-{2-[(2R, 4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]
ethyl}-3, 7-dimethyl-1, 2, 3, 7, 8, 8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate.
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Absorption –Incomplete
Metabolism – bile
t1/2- 2-3 hr
Dose – 5 to 20 mg
 Pravastatin
Pravastatin (marketed as Pravachol or Selektine) is a member of the drug class of
statins, used for lowering cholesterol and preventing cardiovascular disease. Initially known
as CS-514, it was originally identified in a bacterium called Non cardia autotrophica. It is also
hydrophilic and given in the active form.
Pravastatin 10 mg
Systematic (IUPAC) name
(3R,5R)-3,5-dihydroxy-7-((1R,2S,6S,8R,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2
methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)-heptanoic acid
Absorption – Incomplete
CH lowering effect - less
t1/2- 1-3 hr
Dose – 40 to 80mg/day
 Atorvastatin
This newer statin is more potent and appears to have the highest LDL-CH lowering
efficacy. All statins, including atorvastatin, prevent the production of cholesterol in the liver
by blocking HMG-CoA reductase, an enzyme that makes cholesterol.
Atorvastatin 40 mg
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t1/2 - 18 - 24 hr
Dose – 10 to 40 mg
 Rosuvastatin
This is the latest and the most potent statin (10 mg rosuvastatin ≈ 20 mg atorvastatin),
crestor 10 mg.
t1/2 - 18 - 24 hr
LDL-CH reduction – Greater
TG levels – raised
Dose – 5 mg
 Equivalent dosages of statin groups
Table: 1.8. Equivalent dosages of statin groups.
% LDL
Reduction
(approx.)
Atorvastatin Fluvastatin Lovastatin Pravastatin Rosuvastatin Simvastatin
10-20% -- 20 mg 10 mg 10 mg -- 5 mg
20-30% -- 40 mg 20 mg 20 mg -- 10 mg
30-40% 10 mg 80 mg* 40 mg 40 mg 5 mg 20 mg
40-45% 20 mg -- 80 mg* 80 mg* 5–10 mg 40 mg
46-50% 40 mg -- -- -- 10–20 mg 80 mg*
50-55% 80 mg -- -- -- 20 mg --
56-60% -- -- -- -- 40 mg --
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 Adverse effects of statins (Tripathi K.D., 2004)
 Headache
 Nausea
 Bowel upset
 Sleep disturbances
 Rise in serum transaminase, but liver damage is rare
 Muscle tenderness
 Myopathy
 Uses of statins (Richard N., Fogoros MD., 2010)
 Statins improve blood cholesterol levels primarily by inhibiting a liver enzyme called
HMG Co-A reductase.
 Reducing the size of plaques in the arteries.
 Stabilizing plaques, so they are less likely to rupture (and therefore less likely to cause
acute heart attacks).
 Reducing inflammation (which is now thought to be an important component of
plaque formation and rupture).
 Reducing CRP levels
 Decreasing blood clot formation (Blood clot formation at the site of plaque rupture is
the cause of most heart attacks).
NEED
AND
OBJECTIVES
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2. NEED AND OBJECTIVES
Atorvastatin calcium (INN) is the FDA-approved drug for clinical use for the
treatment of lowering blood cholesterol, coronary heart diseases and angina conditions either
alone or in combination with other antihypertensive. Atorvastatin calcium is 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor that is acts as rate limiting step
in cholesterol biosynthesis. Atorvastatin calcium is absorbed rapidly following oral
administration producing peak plasma concentration within 1 to 2 hours with 14 %
bioavailability. Elimination half life is 14 hours and is usually administered in a starting dose
of 10-20 mg daily in order to maintain effective concentration throughout the day. The main
dose related adverse effect is myalgias, muscle cramps, neuropathy. In long term therapy
fluctuations in the plasma concentrations, with high concentration peaks are common for
drugs with rapid absorption and elimination. Such characteristic makes Atorvastatin calcium a
suitable candidate for sustained release delivery.
Immediate release multi particulate drug delivery systems for oral dosing are effective
in achieving immediate onset of action.IR Pellet preparation leads to an increased surface area
as compared to traditional compressed tablet, which considerably decrease the disintegration
time. These are more advantageous in emergency condition such as in case of sudden attack
of strokes. One of the methods of fabricating immediate release formulations is incorporating
of the drug in the pellet and coating with polymer and seal coated with superdisintegrants.
The IRDDS is, thereby improving the oral bioavailability of the drug.
Increased cholesterol levels have been associated with cardiovascular diseases; so,
atorvastatin calcium therefore used in the prevention of strokes and angina. It has a favourable
effect including dementia, lung cancer, and nuclear cataracts.
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The best selling statins is Atorvastatin calcium marketed as Lipitor and Torvast .  So the
present work involves use of immediate release drug delivery system (IRDDS) for
atorvastatin calcium which is rapidly absorbed after administration. This will ensure
minimum fluctuations in the plasma drug concentration and reduced dosing frequency which
will result into improved patient compliance.
Objectives:
Formulate and evaluate the immediate release pellets of atorvastatin calcium.
To study the effect of different superdisintegrants and different concentration of
individual superdisintegrants on the instantaneous disintegration after administration of
capsule.
To study the effect of different polymers and different concentration of individual
superdisintegrants on the in-vitro dissolution studies and release of the drug from the
formulation.
To perform stability studies as per ICH guidelines.
To reduce dosing frequency and improve patient compliance.
PLAN
OF
WORK
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3. PLAN OF WORK
 Literature review
 Selection of drug, superdisintegrants
 Procurement of drug and excipients
 Experimental work
a) Pre formulation studies
 Identification of drug
 By FT-IR spectroscopy
 By melting point
 Physicochemical parameters
 Organoleptic properties
 Solubility profile
 Loss on drying
 Analytical methods
 Determination of λ max
 Development of Caliberation curve of Atorvastatin calcium
 Determination of percentage purity of drug
 Determination of compatibility for drug with
superdisintegrants
 By FT-IR spectroscopy
 By DSC thermal analysis
 Formulation of pellets
 By drug layering method
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 Kinetics of drug release
 Stability studies
LITERATUR E
REVIEW
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4. LITERATURE REVIEW
The basic outcome of this review will be the knowledge as to what data and other
materials are available for operational purposes, which will enable the researcher to specify
his own research problem in meaning full context.
Review on Formulation, Clinical and Analytical studies.
 Balasubramaniam.J., et al., (2008) worked on multi particulate pellets containing
esomeprazole magnesium have been prepared using an extrusion spheronization process,
employing povidone and croscarmellose as non-traditional processing aids. Attempts have
been made to prepare pellets of various sizes and ultimately investigate the levels of enteric
coating that need to be applied in order to achieve a suitable delayed-release dissolution
profile. While acceptable pellets, displaying appropriate drug delayed-release characteristics
have been achieved, it is evident from this initial study that further formulation and processing
refinements, with respect to the formation of the initial pellets, need to be made in order to
create pellets with optimal sphericity characteristics and narrower particle size distributions.
 Damanjeet Ghai ., (2011) had developed Pelletization: an alternate to granulation,
here he concluded that Pelletization represents an efficient pathway for novel drug delivery
system. The potential of this technology lies in the scope for different oral immediate or
controlled delivery systems. Because of its simple design, high efficiency of producing
spherical pellets and fast processing, pelletization has found a special position in
pharmaceutical industry and especially in case of production of multi particulate oral
controlled release dosage forms as compared to granulation. Pelletization technique produces
more spherical pellets and offers more advantages than granulation process. In addition, hot –
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melt extrusion method has provided a new, wider platform to produce spherical pellets of
drugs which are not stable or have compatibility problems in presence of solvents.
 Dr Fahan Jalees ahmed., et al., (2011) had formulated and evaluated the Acyclovir
Capsules. Hydrodynamic Balanced Systems (HBS) can remain in stomach for long periods
and hence can release the drug over a prolonged period of time. The aim of the present study
was to develop a hydro dynamically balanced system of acyclovir as single- unit floating
capsules. Low- density polymers were used for formulation and development of these floating
capsules. The capsules were prepared by physical blending of acyclovir and various polymers
in different ratios. The formulation was optimized on the basis of in- vitro buoyancy and in-
vitro release in 0.1 N HCl. HPMC K4M gave the best in-vitro percentage release and was
found as the optimized formulation. By fitting the data into zero –order, first order and
Higuchi models, we concluded that the release followed zero-order kinetics, as the correlation
coefficient (R value) was higher for zero-order release.
 Ganesh Shete., et al., (2010) were developed solid state characterization of
commercial crystalline and amorphous atorvastatin calcium samples. Atorvastatin calcium
(ATC) , an anti-lipid BCS class II drug is marketed in crystalline and amorphous solid
forms.The objective of this study was to perform solid state characterization of commercial
crystalline and amorphous ATC drug samples available in the market. Six samples each of
crystalline and amorphous ATC were characterized using X-ray powder
diffractometry(XRPD) , differential scanning calorimetry and thermogravimetric analysis,
Karl fisher titrimetry, microscopy, contact angle and intrinsic dissolution rate. All crystalline
ATC samples were found to be stable form I, however, one sample possessed polymorphic
impurity evidenced in XRPD and DSC analysis. Amongst, the amorphous ATC samples
XRPD demonstrated five samples to be amorphous “form 27”, while, one matched
amorphous “form 23”. Thermal behavior of amorphous ATC samples was compared to
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amorphous ATC samples generated by melt quenching in DSC. ATC was found to be an
excellent glass former with Tg/Tm of 0.95.Residual crystallinity was detected in two of the
amorphous samples by complementary use of conventional and modulated use of DSC
techniques. The wettability and IDR of all amorphous samples was found to be higher than
crystalline samples. In conclusion, commercial ATC samples exhibited diverse solid state
behavior that can impact the performance and stability of the dosage forms.
 Golam Kibria ., et al., (2009) the goal of the present study is to evaluate the influence
of the formulation and operating conditions on pellet preparation by the pan technique. The
effect of initial core weight on the physical parameters of pellets as well as to conduct
stability study was also the goal of this study. For this domperidone maleate was selected as
the model drug. Pellets were prepared by layering of powdered drug on sugar-based cores.
Inert cores were intermittently treated with micronized drug powder and binding solution.
This treatment led to the formation of multiple layers of drug particles around an inert core
resulting in the production of pellets that can further be coated by different polymers to obtain
modified release formulations. Scanning electron microscopy was employed to image the
surface morphology of the prepared pellets. Drug loading efficiency, percentage yield, size,
and shape uniformity of pellets were increased along with increasing the initial core weight.
Drug content and dissolution study were performed by following HPLC and UV-Visible
method. About 50% and 80% drug was released within 7.72 m and 13.66 m respectively in
0.1N HC l media (pH 1.2). Physical appearance of the prepared pellets, potency, moisture
content, pellets size and shape, dissolution data, release rate constant, diffusion exponent
(P<.05) over the stability period showed that the system is efficient for the production of
highly stable formulations.  This study also showed the good performance of the conventional
coating pan system in obtaining instant release domperidone pellets prepared by the powder
layering technique.
Atorvastatin Calcium Immediate Release Pellets Literature Review
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 53
 Jakob Kristensen., et al., (2005) were developed the use of different grades of
microcrystalline cellulose (MCC) and lactose in a direct pelletization process in a rotary
processor. For this purpose, a mixed 2- and 3-level factorial study was performed to
determine the influence of the particle size of microcrystalline cellulose (MCC) (60,80 and
100) and lactose (30, 40, and 60 &100), as well as MCC type (Avicel and Emcocel) on the
pelletization process and the physical properties of the prepared pellets. A 1:4 mixture of
MCC and lactose was applied, and granulation liquid was added until a 0.45 Nm increase in
the torque of the friction plate was reached. All combinations of the 3 factors resulted in
spherical pellets of a high physical strength. The particle size of MCC was found to have no
marked effect on the amount of water required for agglomerate growth or on the size of the
resulting pellets. An increasing particle size of lactose gave rise to more spherical pellets of a
more narrow size distribution as well as higher yields. The MCC type was found to affect
both the release of the model drug from the prepared pellets and the size distribution.
Generally, the determined influence of the investigated factors was small, and direct
pelletization in a rotary processor was found to be a robust process, insensitive to variations in
the particle size and type of MCC and the particle size of lactose.
 Kammali Lavanya., et al., (2011) Pelletization Technology: a quick review.
Pelletization process first came into existence way back during the 1950s, when the first
product was introduced to the market. These pelletized dosage forms have gained popularity
considerably from then because of their distinct advantages, such as ease of capsule filling
because of better flow properties of the perfectly spherical pellets; enhancement of drug
dissolution; ease of coating; sustained, controlled, or site-specific delivery of the drug from
coated pellets; uniform packing; even distribution in the GI tract; and less GI irritation.
Pelletized dosage forms can be prepared by a number of techniques, including drug layering
on non pareil sugar or microcrystalline cellulose beads, spray drying, spray congealing, roto
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granulation, hot- melt extrusion, and spheronization of low melting materials or extrusion –
spheronization of wet mass. The present review outlines the recent findings on the
manufacturing and evaluation of spherical pellets. The techniques namely extrusion-
spheronization, hot melt extrusion, freeze pelletization, cryopelletization have been discussed
along with formulation requirements for the process, parameters affecting pelletization.
Evaluation of quality of the pellets is discussed with reference to the size distribution, shape,
surface morphology, specific surface area, friability, tensile strength.
 Lakshmi Narasaiah .V., et al., (2011) were developed Enhancement of dissolution
rate of atorvastatin calcium using solid dispersions by dropping method. It may be concluded
that the prepared solid dispersions were extended to various characterizations. The solubility
and dissolution studies showed there is a possibility of improved solubility of ATC through
solid dispersion with Poly ethylene glycol 6000 than with Polyethylene glycol 4000. The
dissolution rate of ATC from solid dispersions with PEG 6000 improved to more than 38.63%
compared to the pure drug. Further, all the solid dispersions performed better than the
corresponding physical mixtures. Also, the saturation solubility of the drug when formulated
into solid dispersion with the polymer was higher than that of phase solubility achieved in the
presence of the polymer. IR spectra indicated no well-defined interaction between the drug
and polymer. A maximum increase in dissolution rate was obtained with ATC: PEG 6000
solid dispersion with a weight ratio of 1:3. PEG 6000 dispersion by dropping method showed
faster dissolution rate when compared with that of PEG 4000 and pure drug.
 Lori A. Dostal., et al., (1996) department of Pathology and Experimental Toxicology,
Parke – Davis Pharmaceutical Research, division of Wamer- Lambert Company Ann Arbor,
Department of pharmacokinetics and drug metabolism, and these studies demonstrates no
adverse effects of atorvastatin on fertility and reproduction in rats at doses up to 175 and 225
mg/kg no- effect dose.
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 Michael E. Maragoudakis ., et al., (1970) On the mode of action of Lipid-lowering
agents, kinetics of the inhibition in vitro of rat acetyl coenzyme A carboxylase, Rat liver
acetyl coenzyme A carboxylase was purified about 200- fold and the inhibition of this enzyme
by certain hypolipidemic drugs was studied. The inhibition was more pronounced if the drugs
were added before rather than after the citrate activation of the enzyme. Kinetic analysis
revealed non competitive inhibition of the drugs with respect to the substrates acetyl-CoA,
ATP and HCO3- and competitive inhibition with respect to the activator, citrate. Sucrose
density gradient centrifugations showed that the drugs reverse the aggregating effect of citrate
to form the active polymeric forms of the enzyme from the inactive monomers. Arrhenius
plots and heat- inactivation studies suggest gross conformational changes of the enzyme
protein in the presence of the drugs.
 Mustafa Sinan Kaynak., et al., (2007) worked on Formulation of Controlled Release
Glipizide Pellets Using Pan Coating  Method  by using Eudragit RL 100 PM and Eudragit RS
100 PM as coating polymers PIII 200 ml (RL1OO-17G) formulation was significantly lower
than the previous formulations as a ratio of 70% of drug is released in 14 hrs. They concluded
that method is suitable for preparation.
 N. Arun kumar., et al., (2009) were formulated preparation and solid state
characterization of atorvastatin  nanosuspensions for enhanced solubility and dissolution. In
this study an attempt was made to improve the solubility and dissolution characteristics of a
poorly soluble drug (atorvastatin calcium) using nanosuspension technology. Nanoparticles
were characterized in terms of size and morphological characteristics. Saturation solubility
and dissolution characteristics were investigated and compared to commercial drug.
Crystalline of the drug was also evaluated by performing thermal gravimetric analysis (TGA),
differential scanning calorimetry (DSC) and powder X- ray diffraction (PXRD) to denote
eventual transformation to amorphous state during the homogenization process. Through this
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study, it has been shown that the crystalline state of drug is reduced following particle size
reduction and dissolution rates of amorphous atorvastatin calcium nanoparticles were highly
increased in comparision with commercial drug by the enhancement of intrinsic dissolution
rate and reduction of particle size, resulting in an increased surface area.
 Pandey Shivanand., et al., (2009) worked on Design, Optimization and Physical and
Chemical Evaluation of Domperidone Pellets optimization and in-vitro evaluation by using
sodium lauryl sulphate at different concentration for increasing the release rate. Organoleptic
and preformulation studies are conducted formulation of Domperidone pellets containing 0.
06% sodium lauryl sulphate, in formulation F-7 can be taken as an ideal or optimized
formulation of drug layering pellets.
 Parag A. Kulkarni., et al., (2010) Pelletization techniques as a Pharmaceutical tool
in the multi particulate drug delivery system: a review, Conventional medication systems that
need frequent dosing are always with problems. So there is thrust in the area of
pharmaceutical research to develop novel formulations, which will enhance the therapeutic
efficacy of the existing drug. This is less costly as compared to discover new drug. Past few
years multi particulate drug delivery system has emerged as a tool for the delivery of the
drugs. These forms play major role in the design of solid dosage form because of their
characteristic properties and flexibility found in their manufacturing .Use of pellets as a
vehicle in multi particulate drug delivery system has received significant attention. This
review focuses on the different pelletization techniques with their merits, demerits and its
characterization, as a tool in the multi particulate drug delivery system.
 R.Lankas., et al., (2004) Merck research laboratories, West point, Pennsylvania has
reported that “The role of maternal toxicity in atorvastatin- induced developmental toxicity”.
The result of excessive maternal toxicity, which most likely involves a nutritional deficiency
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associated with fore stomach lesions and reduced maternal food intake. Birth Defects Res B
71:111-123, ©2004 Wiley-Liss, Inc.
 Rekkas., et al., (2008) worked on the effect of rotor speed, amount of water sprayed,
and atomizing air pressure on the geometric mean diameter and geometric standard deviation
of pellets produced in a fluid-bed rotor granulator using a 23 factorial design and an
optimization technique. Pellets were prepared by wet granulation. Equal amounts of
microcrystalline cellulose, a-lactose monohydrate, and distilled water were used as the
granulation liquid. The size and the size distribution of the pellets were determined by sieve
analysis. The size of the pellets was found to be dependent on the amount of water added,
while an increase in rotor speed decreased their size. Both factors were found to be
statistically significant (P < 0.05). The effect of atomizing air pressure on pellet size was not
statistically significant. None of the 3 factors significantly affected the geometric standard
deviation of the pellets. The rotor speed and the amount of water sprayed were further
selected in order to construct a mathematical model that correlates these factors with the
geometric mean diameter of the pellets. For this purpose, the optimization technique 32 was
used. The derived equation described the relationship between the selected factors and the
size of the pellets. As a result, the experimental design techniques applied were found to be
suitable in optimizing the pelletization process carried out in a fluid-bed rotor granulator.
 Sachin V. Wankhede., et al., (2010) were developed formulation and stabilization of
atorvastatin tablets. The present study is planned to develop atorvastatin calcium amorphous
into immediate release tablets. Pre formulation studies and drug–excipient compatability
studies was done initially and results obtained were directs the way and method of
formulation. Pre formulation, drug- excipient compatibility, prototype formulation carried out
for the highest dose of atorvastatin calcium (80 mg) and optimized to get the final formula.
Atorvastatin calcium (amorphous) is highly susceptible to oxidation and hydrolysis. So wet
Atorvastatin Calcium Immediate Release Pellets Literature Review
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 58
granulation method was avoided. All the mentioned batches were done by dry granulation
method by roller compaction. Granules were evaluated for tests such as loss on drying (LOD),
bulk density, tapped density, compressibility index, Hausner’s ratio and sieve analysis before
compression. Tablets were tested for weight variation, hardness, friability, thickness and
dissolution. In-vitro dissolutions were performed and the formulations F1 and F2 values were
calculated. Dissolution profile of F5 was matched perfectly with the innovator formulation
and F2 value was found to be excellent. Also the impurity profile and stability result of F5
was found to be excellent. It can be concluded that the immediate release tablet was beneficial
for delivering the drug which needs faster release to achieve the immediate action.
 Salam W. Ahjel., et al., (2009) were developed the enhancement of solubility and
dissolution rate of different forms of atorvastatin calcium in direct compression tablet
formulas. Atorvastatin , as a synthetic lipid- lowering agent, is an inhibitor of 3-hydroxy-3-
methyl-glutaryl-coenzyme A(HMG-CoA) reductase which catalyzes the conversion of HMG-
CoA to mevalonate , an early rate –limiting step in cholesterol synthesis. The bioavailability
of atorvastatin is one of the key parameters for its therapeutic use and is dependent on the
form of the atorvastatin calcium to be used in the pharmaceutical formulation. The patient
should take a constant therapeutic daily dose, regardless to the pharmaceutical formulation of
the ATC. The major finding of this study was that the addition of buffering agent will
dramatically increase both, the solubility and dissolution rate of ATC regardless to the form
used in the preparation of the direct compression formulas. The results were showed that it
was possible to provide therapeutic equivalence of ATC in the pharmaceutical formulation
regardless to the form used in the formulation.
 Singh. SK., et al., (2009) worked on Pellets are agglomerates of fine powders or
granules of bulk drugs and excipients. They consist of small, free flowing, spherical or semi-
spherical solid units, typically from about 0.5mm to 1.5mm, and are intended usually for oral
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administration. Pellets can be prepared by many methods, the compaction and drug-layering
being the most widely used today. The study was undertaken with an aim to develop delayed
release micropellet dosage form for Lansoprazole which is a benzimidazole antiulcer agent
and is one of the most widely used drugs for treating mild and severe ulcers. The approach of
the present study was to make a comparative evaluation among these polymers and excipients
and to assess the effect of physicochemical nature of the active ingredients on the drug release
profile. The prototype formulation of micro pellets were prepared using the fluid bed coater
(FBC) with the air pressure 2.0 bar and the spray rate 10-15ml/min. Temperature of bed is
varied from 35°C to 50°C and inlet temperature is varied from 50°C to 70°C and the effect of
various parameter were observed such as air pressure, inlet and outlet temperature of FBC, it
is observed that at high pressure the pellets are breaking. For bed and inlet temperature it is
observed that at low temperature lumps are curing in the formulation and at 2.0 bar air
pressure, inlet temperature 60°C and bed temperature of 40°C is reliable for solution flow rate
10-15ml/min. Concerning results of prototype preparation of  Lansoprazole the micro pellets
were prepared using HPMC E5 polymer as release retardant in three different concentration
i.e. 40%, 50%, 60% with three different concentration 8%, 10%, 12% of NaOH and Acrycoat
L30D solution was used for enteric coating. Formulated micro pellets showed delayed in-
vitro dissolution behavior, probably due to optimized concentration of polymer. The micro
pellets drug was stable at room temperature, 25°C/60% RH, 30°C/65% RH and 40°C/75%
RH as per ICH guidelines, after 3 months.
 Subhadeep Chowdhury., et al., (2010) had developed a statistical optimization of
fixed dose combination of glimepiride and atorvastatin calcium in immediate release tablet
formulation. Long term administration of oral hypoglycemic drugs has been reported to be
associated with increased cardiovascular mortality as compared to treatment with diet alone or
diet with insulin. For this complication atorvastatin calcium can be used to reduce the
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cardiovascular mortality. The objective of the present study was to evaluate the effects of two
factors (amount of CMC sodium and SSG) on drug release of atorvastatin calcium and
glimepiride from the tablet in order to optimize the formulation by 2 factor 3 level factorial
design. Two independent variables taken were CMC sodium and SSG. The evaluated
response were percentage release of atorvastatin calcium in 60 min(y1) and percentage release
of glimepiride in 60 min(y2) was taken as a response variables. Drug release was measured in
USP 2 apparatus using 900 ml 0.05 M phosphate buffer (pH 6.8) solution at a rotation speed
of 75 rpm. The optimized formulation produced dissolution profiles that were closed to
predicted values.
 Tatsuya Ishikawa., et al., (2001) Department Of Pharmaceutics and
Biopharmaceutics, Showa Pharmaceutical University, Preparation of rapidly disintegrating
tablet using new types of microcrystalline cellulose (PH-M Series) and low substituted-
Hydroxypropylcellulose or spherical sugar granules by direct compression method, compared
to this method in industry we have prepared the same formula for the direct compression
method and result will be obtained, chemical and Pharmaceutical Bulletin, Vol. 49, No.2 134.
 Thomayant prueksaritanont., et al., (2002) Department of drug Metabolism, Merck
research Laboratories, West point, Pennsylvania, Glucuronidation of statins in animals and
Humans. A novel Mechanism of Statin Lactonization may play an important role, albeit
previously unrecognized, role in the conversion of active HMG-CoA reductase inhibitors to
their latent delta lactone forms. Vol. 30, issue 5, 505-512.
 Venkatesh DP., et al., (2008) formulated the orodispersible tablet of Ambroxol
hydrochloride. Since the drug was very bitter to taste, is masked with the use of ion exchange
resins like Indion- 204 and Indion – 234 which also act as super disintegrants. Tablets with
both the resins had shown quick disintegrating features i.e., within 20 sec and also the
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dispersion not showing any bitter taste, indicating the capability of ion exchange resins used,
both as taste masking and super disintegrating agents.
DRUG AND
EXCIPIENT ’S
PROFILE
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5. DRUG AND EXCIPIENT’S PROFILE
5.1. DRUG PROFILE
(Merck Index, 1997; CIMS, 2012; file:///H:/ATORVASTATIN CALCIUM.htm)
Atorvastatin calcium - (HMG- CoA reductase inhibitor).
Atorvastatin calcium is a synthetic lipid-lowering agent. Atorvastatin is an inhibitor of
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the
conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol
biosynthesis.
In adult patients without clinically evident coronary heart disease, but with multiple
risk factors for coronary heart disease such as age >/= 55 years, smoking, hypertension, low
HDL-C, or a family history of early coronary heart disease, Lipitor is indicated to:
 Reduce the risk of myocardial infarction
 Reduce the risk for revascularization procedures and angina.
 Proprietary Name: LIPITOR, CARDYL, SORTIS, TORVAST.
 Structure:
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 IUPAC NAME: [R-(R*, R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-
3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid, calcium salt (2:1)
trihydrate.
 CAS number: 134523-00-5.
 Molecular weight: 1209.42
 Molecular formula: (C33H34FN2O5)2Ca.3H2O
 Physical State: Solid.
 Melting Point: 159.2-160.7oC
 Water Solubility: Sodium salt soluble in water, 20.4 ug/mL (pH 2.1), 1.23 mg/Ml
(pH 6.0)
Phase 1 Metabolising Enzyme (1-st Step of Metabolism): CYP3A4
Table: 5.1. Primary drug targeting
Name HMG-CoA Reductase
Gene Name HMGCR
Synonyms 3-hydroxy-3-methylglutaryl-coenzyme A reductase; EC 1.1.1.34;
HMG-CoA reductase
General
Function
Lipid transport and metabolism
Specific
Function
This transmembrane glycoprotein is involved in the control of
cholesterol biosynthesis. It is the rate-limiting enzyme of sterol
biosynthesis
Pathway map00100 Biosynthesis of steroids
Reaction (R)-mevalonate + CoA + 2 NADP+ = (S)-3-hydroxy-3-methylglutaryl-
CoA + 2 NADPH + 2 H+
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 Description:
Atorvastatin calcium is a white to off white crystalline powder that is insoluble
in aqueous solutions of pH4 and below. Atorvastatin calcium is very slightly soluble in
distilled water, pH 7.4 phosphate buffer. And Acetonitrile, slightly soluble in ethanol and
freely soluble in methanol.
CLINICAL PHARMACOLOGY:
 Mechanism
Figure: 5.1. Mechanism of statins.
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-
limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzymeA to mevalonate, a
precursor of sterols, including cholesterol. Cholesterol and triglycerides circulate in the
bloodstream as part of lipoprotein complexes. With ultracentrifugation, these complexes
separate into HDL (high-density lipoprotein), IDL (intermediate-density lipoprotein), LDL
(low-density lipoprotein), and VLDL (very-low-density lipoprotein) fractions. Triglycerides
(TG) and cholesterol in the liver are incorporated into VLDL and released into the plasma for
delivery to peripheral tissues. LDL is formed from VLDL and is catabolized primarily
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through the high-affinity LDL receptor. Clinical and pathologic studies show that elevated
plasma levels of total cholesterol (total-C), LDL-cholesterol (LDL-C), and Apo-lipoprotein B
(Apo- B) promote human atherosclerosis and are risk factors for developing cardiovascular
disease, while increased levels of HDL-C are associated with a decreased cardiovascular risk.
In animal models, Atorvastatin calcium lowers plasma cholesterol and lipoprotein levels
by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the
number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of
LDL; Atorvastatin calcium also reduces LDL production and the number of LDL particles.
Atorvastatin calcium reduces LDL-C in some patients with homozygous familial
hypercholesterolemia (FH), a population that rarely responds to other lipid-lowering
medication(s).
A variety of clinical studies have demonstrated that elevated levels of total-C, LDL-C,
and apo B (a membrane complex for LDL-C) promote human atherosclerosis. Similarly,
decreased levels of HDL-C (and its transport complex, apo A) are associated with the
development of atherosclerosis. Epidemiologic investigations have established that
cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C, and
inversely with the level of HDL-C.
Atorvastatin calcium reduces total-C, LDL-C, and Apo B in patients with homozygous
and heterozygous FH, non-familial forms of hypercholesterolemia, and mixed dyslipidemia.
Atorvastatin calcium also reduces VLDL-C and TG and produces variable increases in HDL-
C and Apo-lipoprotein A-1. Atorvastatin calcium reduces total-C, LDL-C, VLDL-C, Apo B,
TG, and non-HDL-C, and increases HDL-C in patients with isolated hypertriglyceridemia.
Atorvastatin calcium reduces intermediate density lipoprotein cholesterol (IDL-C) in patients
with dysbetalipoproteinemia.
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Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including VLDL,
intermediate density lipoprotein (IDL), and remnants, can also promote atherosclerosis.
Elevated plasma triglycerides are frequently found in a triad with low HDL-C levels and
small LDL particles, as well as in association with non-lipid metabolic risk factors for
coronary heart disease. As such, total plasma TG has not consistently been shown to be an
independent risk factor for CHD. Furthermore, the independent effect of raising HDL or
lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been
determined.
 Pharmacodynamics
Atorvastatin as well as some of its metabolites are pharmacologically active in humans.
The liver is the primary site of action and the principal site of cholesterol synthesis and LDL
clearance. Drug dosage rather than systemic drug concentration correlates better with LDL-C
reduction. Individualization of drug dosage should be based on therapeutic response.
 Pharmacokinetics and Drug Metabolism
 Absorption
Atorvastatin is rapidly absorbed after oral administration; maximum plasma
concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion to
atorvastatin dose. The absolute bioavailability of atorvastatin (parent drug) is approximately
14% and the systemic availability of HMG-CoA reductase inhibitory activity is
approximately 30%. The low systemic availability is attributed to pre systemic clearance in
gastrointestinal mucosa and/or hepatic first-pass metabolism. Although food decreases the
rate and extent of drug absorption by approximately 25% and 9%, respectively, as assessed by
Cmax and AUC, LDL-C reduction is similar whether atorvastatin is given with or without
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food. Plasma atorvastatin concentrations are lower (approximately 30% for Cmax and AUC)
following evening drug administration compared with morning. However, LDL-C reduction
is the same regardless of the time of day of drug administration.
 Distribution
Mean volume of distribution of atorvastatin is approximately 381 liters. Atorvastatin is
≥98% bound to plasma proteins. A blood/plasma ratio of approximately 0.25 indicates poor
drug penetration into red blood cells. Based on observations in rats, atorvastatin is likely to be
secreted in human milk.
 Metabolism
Atorvastatin is extensively metabolized to ortho and parahydroxylated derivatives and
various beta-oxidation products. In-vitro inhibition of HMG-CoA reductase by ortho and para
hydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of
circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. In-
vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 3A4,
consistent with increased plasma concentrations of atorvastatin in humans following
coadministration with erythromycin, a known inhibitor of this Isozyme. In animals, the ortho-
hydroxy metabolite undergoes further glucuronidation.
 Excretion
Atorvastatin and its metabolites are eliminated primarily in bile following hepatic
and/or extra-hepatic metabolism; however, the drug does not appear to undergo Entero
hepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is
approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20
to 30 hours due to the contribution of active metabolites. Less than 2% of a dose of
atorvastatin is recovered in urine following oral administration.
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 Special Populations
 Geriatric
Plasma concentrations of atorvastatin are higher (approximately 40% for Cmax and 30%
for AUC) in healthy elderly subjects (age ≥65 years) than in young adults. Clinical data
suggest a greater degree of LDL-lowering at any dose of drug in the elderly patient population
compared to younger adults.
 Gender
Plasma concentrations of atorvastatin in women differ from those in men
(approximately 20% higher for Cmax and 10% lower for AUC); however, there is no clinically
significant difference in LDL-C reduction with Atorvastatin calcium between men and
women.
 Renal Insufficiency
Renal disease has no influence on the plasma concentrations or LDL-C reduction of
atorvastatin; thus, dose adjustment in patients with renal dysfunction is not necessary.
 Hemodialysis
While studies have not been conducted in patients with end-stage renal disease,
hemodialysis is not expected to significantly enhance clearance of atorvastatin since the drug
is extensively bound to plasma proteins.
 Hepatic Insufficiency
In patients with chronic alcoholic liver disease, plasma concentrations of atorvastatin
are markedly increased. Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A
disease. Cmax and AUC are approximately 16-fold and 11-fold increased, respectively, in
patients with Childs-Pugh B disease.
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 Dosage and administration
The patient should be placed on a standard cholesterol-lowering diet before receiving
atorvastatin and should continue on this diet during treatment with atorvastatin.
 Drug  interactions
The risk of myopathy during treatment with drugs of this class is increased with
concurrent administration of cyclosporine, fibric acid derivatives, niacin (nicotinic acid),
erythromycin, azole antifungals.
ANTACID
When atorvastatin and Maalox OTC suspension were co-administered, plasma
concentrations of atorvastatin decreased approximately 35%. However, LDL-C reduction was
not altered.
ANTIPYRINE
Because atorvastatin does not affect the pharmacokinetics of antipyrine, interactions
with other drugs metabolized via the same cytochrome isozymes are not expected.
COLESTIPOL
Plasma concentrations of atorvastatin decreased approximately 25% when colestipol
and atorvastatin were co-administered. However, LDL-C reduction was greater when
atorvastatin and colestipol were co-administered than when either drug was given alone.
CIMETIDINE
Atorvastatin plasma concentrations and LDL-C reduction were not altered by co-
administration of cimetidine.
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DIGOXIN
When multiple doses of atorvastatin and digoxin were coadministered, steady-state
plasma digoxin concentrations increased by approximately 20%. Patients taking digoxin
should be monitored appropriately.
ERYTHROMYCIN
In healthy individuals, plasma concentrations of atorvastatin increased approximately
40% with co-administration of atorvastatin and erythromycin, a known inhibitor of
cytochrome P450 3A4.
ORAL CONTRACEPTIVES
Co-administration of atorvastatin and an oral contraceptive increased AUC values for
norethindrone and ethinyl estradiol by approximately 30% and 20%. These increases should
be considered when selecting an oral contraceptive for a woman taking atorvastatin.
WARFARIN
Atorvastatin had no clinically significant effect on prothrombin time when administered
to patients receiving chronic warfarin treatment.
 Endocrine function
HMG-CoA reductase inhibitors interfere with cholesterol synthesis and theoretically
might blunt adrenal and/or gonadal steroid production. Clinical studies have shown that
atorvastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve.
The effects of HMG-CoA reductase inhibitors on male fertility have not been studied in
adequate numbers of patients. The effects, if any, on the pituitary-gonadal axis in
premenopausal women are unknown. Caution should be exercised if an HMG-CoA reductase
inhibitor is administered concomitantly with drugs that may decrease the levels or activity of
endogenous steroid hormones, such as ketoconazole, spironolactone and cimetidine.
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 CNS toxicity
Brain hemorrhage was seen in a female dog treated for 3 months at 120 mg/kg/day.
Brain hemorrhage and optic nerve vacuolation were seen in another female dog that was
sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day. The
120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma
area-under-the-curve (AUC, 0-24 hours) based on the maximum human dose of 80 mg/day. A
single tonic convulsion was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one
at 120 mg/kg/day) in a 2-year study. No CNS lesions have been observed in mice after
chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100
mg/kg/day. These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC
(0-24) based on the maximum recommended human dose of 80 mg/day.
CNS vascular lesions, characterized by peri-vascular haemorrhages, edema, and
mononuclear cell infiltration of peri-vascular spaces, have been observed in dogs treated with
other members of this class. A chemically similar drug in this class produced optic nerve
degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a
dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than
the mean drug level in humans taking the highest recommended dose.
EXCIPIENT ’S
PROFILE
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5.2. EXCIPIENT’S PROFILE
 Excipients
Substances, other than the active ingredient, which have been appropriately evaluated
for safety and are included in a drug delivery system to provide support.
The excipients used must have following characteristics
 They must be stable both physically, chemically and must be biologically
inactive.
 It must be free from microbial contamination
 Excipients used in pellet formulation must be accepted by regulatory agencies
and should meet the entire current regulatory requirement.
Excipient’s used are:
a) Hydroxy propyl methyl cellulose.
b) Croscarmellose sodium.
c) Crospovidone.
d) Sodium starch glycolate.
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1. Hypromellose (Raymond C Rowe., et al., 2003)
 Nonproprietary Names:
BP: Hypromellose                                  JP: Hydroxypropylmethylcellulose
PhEur: Hypromellosum                         USP: Hypromellose
 Synonyms:
Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; Methocel;
methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; Metolose; Tylopur.
 Chemical Name: Cellulose hydroxyl propyl methyl ether.
 CAS Registry Number: [9004-65-3]
 Molecular weight: 10,000-15,00,000
 Structural Formula:
Where R is H, CH3, or CH3CH (OH) CH2
 Functional Category:
Coating agent; film-former; rate-controlling polymer for sustained release; stabilizing
agent; suspending agent; tablet binder; viscosity-increasing agent.
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 Applications in Pharmaceutical Formulation or Technology:
Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical
formulations. In oral products, hypromellose is primarily used as a tablet binder, in film-
coating, and as matrix for use in extended-release tablet formulations.  High-viscosity grades
may be used to retard the release of drugs from a matrix at levels of 10–80% w/w in tablets
and capsules. Lower-viscosity grades are used in aqueous film-coating solutions, while
higher-viscosity grades are used with organic solvents.
 Description:
Hypromellose is an odourless and tasteless, white or creamy-white fibrous or granular
powder.
 Typical Properties:
Acidity/alkalinity: pH = 5.5–8.0 for a 1% w/w aqueous solution.
Density (bulk) : 0.341 g/cm3.
Density (tapped) : 0.557 g/cm3.
Density (true) : 1.326 g/cm3.
Melting point : browns at 190–200°C; chars at 225–230°C.
Glass transition temperature is 170–180°C.
 Moisture content: Hypromellose absorbs moisture from the atmosphere; the amount
of water absorbed depends upon the initial moisture content and the temperature and relative
humidity of the surrounding air.
 Solubility: Soluble in cold water, forming a viscous colloidal solution; practically
insoluble in chloroform, ethanol (95%), and ether, but soluble in mixtures of ethanol and
dichloromethane, mixtures of methanol and dichloromethane, and mixtures of water and
alcohol.
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 Viscosity (dynamic): A wide range of viscosity types are commercially available.
Aqueous solutions are most commonly prepared, although hypromellose may also be
dissolved in aqueous alcohols such as ethanol and propan-2-ol provided the alcohol content is
less than 50% w/w.
Typical viscosity values for 2% (w/v) aqueous solutions of Methocel (Dow Chemical Co.).
Viscosities measured at 20°C.
Methocel product USP 28 designation Nominal viscosity (mPa s)
Methocel K100 Premium LVEP 2208 100
Methocel K4M Premium 2208 4000
Methocel K15M Premium 2208 15 000
Methocel K100M Premium 2208 100 000
Methocel E4M Premium 2910 4000
Methocel F50 Premium 2906 50
Methocel E10M Premium CR 2906 10 000
Methocel E3 Premium LV 2906 3
Methocel E5 Premium LV 2906 5
Methocel E6 Premium LV 2906 6
Methocel E15 Premium LV 2906 15
Metolose 60SH 2910 50, 4000, 10 000
Metolose 65SH 2906 50, 400, 1500, 4000
Metolose 90SH 2208 100, 400, 4000, 15, 000
 Stability and Storage Conditions:
Hypromellose powder is a stable material, although it is hygroscopic after drying.
Solutions are stable at pH 3–11. Increasing temperature reduces the viscosity of solutions.
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Hypromellose undergoes a reversible sol–gel transformation upon heating and cooling,
respectively.
 Incompatibilities:
Hypromellose is incompatible with some oxidizing agents. Since it is nonionic,
hypromellose will not complex with metallic salts.
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2. Crospovidone (Raymond C Rowe., et al.,2003)
 Nonproprietary Name: Crospovidone.
 Synonyms : BP : Crospovidonum;
PhEur: Polyplasdone XL;
USPNF: Polyvinylpolypyrrolidone.
 Chemical Name:
1-Ethenyl-2-pyrrolidinone homopolymer.
 CAS number: (9003-39-8).
 Description:
Crospovidone is a white to creamy-white, finely divided, free flowing,
practically tasteless, odourless or nearly odourless, hygroscopic powder.
 Empirical Formula and Molecular Weight: (C6H9NO)n, 2,500 – 2,50,00,000
g·mol−1
 Molecular structure:
 Functional Category: Tablet disintegrant
 Solubility: Practically insoluble in water and most common organic solvents.
 Stability and Storage Conditions: Since crospovidone is hygroscopic, it should be
stored in an airtight container in a cool, dry place.
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 Incompatibilities:
Crospovidone is compatible with most organic and inorganic pharmaceutical
ingredients. When exposed to a high water level, crospovidone may form molecular adducts
with some materials.
 Applications:
Crospovidone is a water-insoluble tablet disintegrant and dissolution agent used at
2-5 % concentration in tablets prepared by direct compression or wet and dry-granulation
methods. It can also be used as a solubility enhancer.
 Related Substances: Crospovidone,  povidone.
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3. Sodium Starch Glycolate (Raymond C Rowe.,et al.,2003)
 Non proprietary names : BP: sodium starch glycolate
PhEur: Carboxy methyl amylum natricum
USPNF: sodium starch glycolate
 Synonyms:
Explotab;  Primogel;  Vivastar.  Carboxymethyl starch,  sodium salt.
 Chemical Name:
Sodium carboxymethyl starch.
 CAS number: (9063-38-1)
 Description:
It is a white or almost white free-flowing very hygroscopic powder.
The Ph Eur states that when examined under a microscope it is seen to consist of:
granules irregularly shaped, ovoid or pear-shaped, 30–100 mm in size, or rounded,10–35 mm
in size; compound granules consisting of 2–4 components occur occasionally; the granules
have an eccentric helium and clearly visible concentric striations. Between crossed Nicole
prisms, the granules show a distinct black cross intersecting at the haulm; small crystals are
visible at the surface of the granules. The granules how considerable swelling in contact with
water.
 Functional Category:
Tablet and capsule disintegrant.
 Solubility:
Practically insoluble in water and insoluble in most organic solvents
Atorvastatin Calcium Immediate Release Pellets Excipients Profile
Page 80
Adhiparasakthi college of Pharmacy, Melmaruvathur.
 Incompatibilities
Sodium starch glycolate is incompatible with ascorbic acid
 Stability and Storage Conditions
Tablets prepared with sodium starch glycolate have good storage properties.
Sodium starch glycolate is stable although very hygroscopic, and should be stored in a well-
closed container in order to protect it from wide variations of humidity and temperature,
which may cause caking. The physical properties of sodium starch glycolate remain changed
for up to 3 years if it is stored at moderate temperatures and humidity
 Applications in Pharmaceutical Formulation
a.   Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant
in capsule and tablet formulations.
b. It is commonly used in tablet prepared by either direct compression or wet
granulation processes.
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4. Croscarmellose sodium (Raymond C Rowe.,et al.,2003)
 Nonproprietary Name: BP:Croscarmellose sodium
PhEur: Carmellosum natricum conexum
USPNF: Croscarmellose sodium.
 Synonyms: Ac-di-sol; carmellosum natricum conexum; Cross-linked
carboxymethylcellulose sodium; Explocel:modified cellulose gum; Nymcel ZSX; Pharmacel
XL; Primellose; Solutab; Vivasol.
 Chemical Name: Cellulose, carboxy methyl ether, sodium salt.
 CAS number: 74811-65-7
 Functional Category: Tablet and capsule disintegrant.
 Description:
Croscarmellose sodium occurs as an odorless, white or grayish-white powder.
 Solubility:
Insoluble in water, although Croscarmellose sodium rapidly swells to 4-8 times
its original volume on contact with water. Practically insoluble in acetone, ethanol and
toluene.
 Stability and Storage Conditions:
Croscarmellose sodium is a stable though hygroscopic material. A model tablet
formulation prepared by direct compression, with Croscarmellose sodium as a disintegrant,
showed no significant difference in drug dissolution after storage at 3000C for 14 months.
Croscarmellose sodium should be stored in a well closed container in a cool, dry place.
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 Incompatibilities:
The efficacy of disintegrant such as Croscarmellose sodium, may be slightly
reduced in tablet formulations prepared by either the wet-granulation or direct compression
process that contain hygroscopic excipients such as sorbitol. Croscarmellose Sodium is not
compatible with strong acids or with soluble salts of iron and some other metals such as
aluminum, mercury and zinc.
 Applications:
a. Croscarmellose sodium is used in oral pharmaceutical formulations as a disintegrant
for capsules, tablets and granules.
b. In tablet formulations, Croscarmellose sodium may be used in both direct-
compression and wet-granulation processes. When used in wet granulations, the
Croscarmellose sodium should be added in both the wet and dry stages of the process (intra
and extra- granularly) so that the wicking and swelling ability of the disintegrant is best
utilized.
c. Croscarmellose sodium at concentrations up to 5% w/w may be used as tablet
disintegrant, although normally 2% w/w is used in tablets prepared by direct compression and
3%w/w in tablet prepared by wet granulation process.
MATERIALS AND
EQUIPMENTS
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6. MATERIALS AND EQUIPMENTS
6.1. Raw materials
Table: 6.1. Raw materials with name of the supplier
S.NO Name of raw material Name of the supplier
1 Atorvastatin calcium Vasavi Lab Pvt.ltd., Maharastra
2 Sodium starch glycolate Richer Health Care, Hyderabad
3 Crospovidone Richer Health Care, Hyderabad
4 Croscarmellose sodium Richer Health Care, Hyderabad
5 Hydroxy propyl methyl cellulose E-15 Richer Health Care, Hyderabad
6 Non pareil seeds Rainbow Health Care Products, Hyderabad
7 Polyvinylpyrolidone K-30 Richer Health Care, Hyderabad
8 Talc Richer Health Care, Hyderabad
9 Potassium dihydrogen phosphate Richer Health Care, Hyderabad
10 Methanol Richer Health Care, Hyderabad
11 Ethanol (95%) Richer Health Care, Hyderabad
12 Sodium hydroxide Richer Health Care, Hyderabad
13 Isopropyl alcohol Richer Health Care, Hyderabad
14 Acetonitrile Richer Health Care, Hyderabad
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6.2. Equipments
Table: 6.2. Equipments with company name
S.NO Name of Equipment Manufacturing Company
1 Electronic balance Shimadzu Scientific instruments, Japan
2 Vernier Caliper Shankar Scientific, Chennai
3 Friabilator Roche Friabilator
4 pH meter Model MP-1 Plus Susima Dharma
5 Hot air oven Minicon Equipments Pvt Ltd.,
6 Dissolution Apparatus LAB INDIA DISSO-2000
7 Double beam spectrophotometer Shimadzu Scientific Instruments, Japan
8 FT-IR Spectrophotometer Shimadzu Scientific Instruments, Japan
9 Coating pan Rinak , kalweka HD410AC
10 Spray gun Rinak , kalweka HD410AC
11 Hardness Tester Dr.schleuniger, pharmatron,USA
12 Digital scanning calorimeter Shimadzu DSC 60 , Japan
13 Bulk density apparatus Indolab VTAP/MATIC-II
14 Standard sieve no(20 and 40#) Jayant scientific IND
EXPERIMENTAL
WORK
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7.1.Pre formulation studies
Pre-formulation testing was an investigation of physical and chemical properties of a
drug substance alone. It was the first step in rational development of dosage form.
7.1.1. Identification of drug
7.1.1.1. Identification by FT-IR spectroscopy (Skoog D.A., et al., 1996; IP, 2007)
Atorvastatin discs were prepared by pressing the Atorvastatin with potassium bromide
and the spectra between 4000-1 to 500-1 cm was obtained under the operational conditions.
The absorption maximums in spectrum obtained with the substance being examined
correspond in position and relative intensity to those in the reference spectrum in Table 8.1
and Figure 8.1.
7.1.1.2. Identification by melting point (IP, 2007)
Melting point of the drug was determined by capillary tube method.
7.1.2. Physicochemical parameters
7.1.2.1. Organoleptic properties
(Lachman L., et al., 1991; Bankar G.S. and Rhodes C.T., 1996)
The colour, odour and taste of the drug were recorded using descriptive terminology.
7.1.2.2. Solubility study (Merck Index., 1997., IP, 2007)
It was important to know about solubility characteristic of a drug in aqueous system,
since they must possess some limited aqueous solubility to elicit a therapeutic response. The
solubility of drug was recorded by using various descriptive terminologies specified in Indian
pharmacopoeia, 2007.The solubility study was shown in Table 8.2.
7. EXPERIMENTAL WORK
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7.1.2.3. Loss on drying: (IP, 2007)
Loss on drying was the loss of weight expressed as percentage w/w resulting from
water and volatile matter of any kind that can be driven off under specified condition. The
accurately weighed 1gm of sample was transferred in stoppered-glass shallow weighing bottle
and accurately weighed the bottle. The bottle was transferred in oven and substance was dried
at 105°C for 3 hours. The bottle was removed from oven and reweighed; loss on drying was
calculated by following equation. It was shown in Table 8.3
= − ×
7.1.3. Analytical methods
7.1.3.1. Determination of λ max (Alka Gupta., et al., 2009)
The absorption maximum of the standard solution was scanned between 200-
400 nm regions on UV-VISIBLE spectrophotometer. The absorption maximum obtained with
the substance being examined corresponds in position and relative intensity to those in the
reference spectrum
7.1.3.2. Development of Caliberation curve of Atorvastatin in methanol
(Alka Gupta., et al., 2009)
25 mg of Atorvastatin Calcium was weighed accurately and transferred into 50 ml
volumetric flask and dissolved in Methanol, after dissolution the volume was made up to the
mark with Methanol (500g/ ml). Further dilution was made by pipetting 1 ml of mother
liquor into 50 ml to acquire 10 g/ ml solution made up with methanol. The absorbance
measurements of these solutions were carried out against methanol as blank at 246 nm. A
calibration curve of Atorvastatin was plotted.
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Preparation of methanol solution (IP, 2007)
Methanol was prepared according to I.P. 2007.
Preparation of stock solution of Atorvastatin in methanol
Accurately weighed 100 mg of Atorvastatin and it was dissolved in little quantity of
100ml of methanol and 1ml of solution was taken & make up to 10ml (100µg/ml) volume was
the same to prepared standard solution having concentration of 100 µg/ ml.
Procedure
From the stock solution, aliquots of 2, 4, 6, 8 and 10 ml were transferred to 10 ml
volumetric flasks and final volume was made to 100ml with methanol. Absorbance values of
these solutions were measured against blank (methanol) at 246 nm using UV-Visible
spectrophotometer.
7.1.3.3 .Development of caliberation curve of Atorvastatin in 6.8 phosphate buffer
(IP, 2007)
Preparation of 6.8 phosphate buffer
Placed the 50 ml of 0.2M potassium dihydrogen phosphate in a 200 ml of volumetric
flask, and added specified volume of 0.2 M sodium hydroxide then added water to volume to
required.
Preparation of 0.2 M sodium hydroxide
Dissolved the sodium hydroxide in water to produce 40 to 60 %w/v solution and
allow to stand and finally added 8 gm of sodium hydroxide in 1000 ml.
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Preparation of 0.2 M potassium dihydrogen phosphate
Dissolved the 27.218 gm of potassium dihydrogen phosphate in water and diluted with
water 1000ml.
Preparation of stock solution of Atorvastatin in 6.8 phosphate buffer
Accurately weighed 100 mg of Atorvastatin was dissolved in little quantity of 100ml of
6.8 phosphate buffer and 1ml of solution was taken & make up to 10ml (100µg/ml) volume
was the same to prepared standard solution having concentration of 100 µg/ ml.
Procedure
From the stock solution, aliquots of 2, 4, 6, 8 and 10 ml were transferred to 10 ml
volumetric flasks and final volume was made to 100ml with 6.8 phosphate buffer.
Absorbance values of these solutions were measured against blank (6.8 phosphate buffer) at
246 nm using UV-Visible spectrophotometer
7.1.3.4. Determination of percentage purity of Drug
(IP, 2007)
Accurately weighed 25 mg of atorvastatin calcium was dissolved in little quantity of
methanol and volume was adjusted to 100 ml with the same to prepare standard solution
having concentration of 250 µg/ ml. From the above solution, aliquots of 3 ml were
transferred to 50 ml volumetric flasks and final volume was made to 50 ml with methanol.
Absorbance values of these solutions were measured against blank methanol at 246 nm using
Shimadzu-1700 Pharmaspec UV-VISIBLE spectrophotometer. The percentage purity of drug
was calculated by using calibration graph method (least square method).
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7.1.4. Determination of drug-superdisintegrants compatibility
(Aulton M.E., 2002., Patil S.V., et al .,2009)
The proper design and formulation of a dosage form requires consideration of the
physical, chemical and biological characteristics of all drug substances and excipients to be
used in the fabricating the product. Each superdisintegrant used in the formulations was
blended with the drug levels that are realistic with respect to the final dosage form.
Figure: 7.1. Compatibility studies
7.1.4.1. Fourier transform infrared (FT-IR) spectroscopy
(Patil S.V., et al., 2009; IP, 2007)
FT-IR study was carried out to check compatibility of drug with superdisintegrants.
Infrared spectrum of Atorvastatin calcium was determined on Fourier transform Infrared
Spectrophotometer using KBr dispersion method. The base line correction was done using
dried potassium bromide. Then the spectrum of dried mixture of drug and potassium bromide
was run followed by drug with various superdisintegrants by using FT-IR spectrophotometer.
The absorption maximums in spectrum obtained with the substance being examined
correspond in position and relative intensity to those in the reference spectrum represented in
table 8.9 and also shown in figure 8.6.
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7.1.4.2. Differential scanning calorimetry (DSC)
(Patil S.V., et al., 2009; Aulton M.E., 2002)
Any possible drug excipients interaction can be studied by thermal analysis. The DSC
study was performed on pure drug, drug+ SSG, drug+ CP and drug+ CCS. The study was
carried out using a DSC. The 2 mg of sample were heated in a hermetically sealed aluminum
pans in the temperature range of 25-300ºc at heating rate of 10ºc /min under nitrogen flow of
30ml/min. The results of DSC analysis were presented in figure 8.7 and table 8.10.
7.2. FORMULATION OF IMMEDIATE RELEASE PELLETS
(Kammali Lavanya., et al., 2011)
The pellets were prepared by Drug layering method, by using a different drug and
superdisintegrants ratios. The formulations were designated as F1, F2, F3, F4, F5 and F6
respectively.
7.2.1 Drug layering method
Drug layering involves the deposition of successive layers of dry powders of
drugs and excipients on preformed nuclei or cores with the help of binding liquids. As powder
layering involves simultaneous application of binding agents and dry powders, hence it
required specialized equipments like spheronizer. The primary requirement in this process
was that the product container should be solid walls with no perforation to avoid powder lose
beneath the product chute before the powder was picked off by the wet mass of pellets that
was being layered.
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 STAGES: Drug loading
Drying
Sub coating
Coating
7.2.2. Figure: 7.2.Flowchart for method of preparation of pellets
Non Pareil
seeds
Drug Loading
Drying
Size separation
Coating
Size separation
Q.C.D analysis
Packing
Dispatch
Drug & Excipients Solvent with
binding material
Subcoating with
seal coating
material solvent
Coating
SR coating with SR
coating solution
QAD Approval
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Table: 7.1.Composition of formulations
INGREDIENTS
(mg)*
FORMULATION *
F1 F2 F3 F4 F5 F6
Atorvastatin calcium
(ATC)
10 10 10 10 10 10
Non pareil
seeds(pellets)
266 254 266 254 266 254
PVP K-30 9 9 9 9 9 9
Isopropyl alcohol q. s q. s q. s q. s q. s q. s
HPMC E15 3 3 3 3 3 3
Crospovidone - - 12 24 - -
Sodium starch
glycolate
12 24 - - - -
Croscarmellose
sodium
- - - - 12 24
Total 300 300 300 300 300 300
*All the quantities are expressed as mg per capsule
7.2.3. Loose Bulk Density (LBD) (Lachman L., et al., 1991)
An accurately weighed powder from each formula was lightly shaken to break any
agglomerates formed and it was introduced into a measuring cylinder. The volume occupied
by the powder was measured which gave bulk volume. The loose bulk density (LBD) of
powder blends was determined using the following formula.
Loose bulk density = Total weight of powder / Total volume of powder
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7.2.4. Tapped bulk density (TBD) (Lachman L., et al., 1991)
An accurately weighed powder from each formula was lightly shaken to break any
agglomerates formed and it was introduced into a measuring cylinder. The measuring cylinder
was tapped until no further change in volume was noted which gave the tapped volume. The
tapped bulk densities (TBD) of powder were determined using the following formula.
Tapped bulk density= Total weight of powder / Total volume of tapped powder
7.2.5. Hausner’s Ratio (Lachman L., et al., 1991)
Hausner’s ratio was determined by following equation,
’ = /
A hausner’s ratio less than 1.25 indicates good flow while greater than 1.5 indicates
poor flow.
7.2.6. Carr’s Compressibility Index (Lachman L., et al., 1991)
It is a simple index that can be determined on small quantities of powder. In theory, the
less compressible a material the more flowable it is.
The compressibility indices of the powder blends was determined using following
formula,
Carr’s Compressibility Index (%) = [(TBD-LBD)/ TBD] x100
Relationship between % compressibility and flowability is shown in the table 7.2.
Table: 7.2. Standard values of Carr’s index
S. NO. Carr’s index Type of flow
1 5-15 Excellent
2 12-16 Good
3 18-21 Fair to passable
4 23-35 Poor*
5 33-38 Very poor*
6 >40 Extremely poor*
* May be improved by glidant
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7.27. Angle of repose (Lachman L., et al., 1991)
The angle of repose was determined by the funnel method. The accurately weighed
powder was taken into a funnel. The height of the funnel was adjusted in such a way that the
tip of the funnel just touched the apex of the heap of the powder. The powder was allowed to
flow through the funnel freely onto the surface. The diameter of the powder cone was
measured. The angle of repose was calculated using the following equation.( ) =
Where ‘h’ and ‘r’ are the height and radius respectively of the powder cone
Table: 7.3. Standard values of Angle of repose
S. NO. Flowability Angle of repose (θ)
1 Excellent <25
2 Good 25-30
3 Passable* 30-40
4 Poor 37-45
5 Very poor >45
* Adding glidant for improving flow
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7.3. EVALUATION OF IMMEDIATE RELEASE PELLETS
7.3.1. Appearance (Lachman L., et al., 1991; Bankar G.S. and Rhodes C.T., 1996)
The capsules were visually observed for morphological characters like color, shape and
size etc.
7.3.2. Physicochemical characteristics
7.3.2.1. Dimension (Thickness and Diameter) (Kammali Lavanya., et al., 2011)
The thickness and diameter of pellets were important for uniformity of pellet size. The
thickness and diameter of the pellet was determined using Vernier calipers (mitutoyo absolute
vernier calipers). Three pellets from each type of formulation were used and average values
were calculated.
7.3.2.2. Pellet Hardness (Ranjana chopra; et al; 2001)
For each formulation, the hardness of 6 pellets was determined using the Dr.
Schieuniger hardness tester. The pellet was held in between the two jaws of the tester. At this
point, reading should be zero Newtons. Then constant force was applied by rotating the knob
until the pellet fractured. The value at this point was noted in Newtons.
7.3.2.3. Percent Friability (Abbaspour MR; et al; 2008 ;)
Friability is the measure of pellet strength. Friability of pellets are determined by using
Erkewa type tablet friabilator for a fixed period of time combined with glass beads of certain
diameter in order to generate abrasion and to generate friability index.  The pellets were then
dedusted and reweighed. A loss of less than 1 % in weight is generally considered acceptable.
Percent friability (% F) was calculated as follows,% = − ×
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7.3.2.4. Weight Variation (IP, 2007; Lachman L., et al., 1991)
To find out weight variation 20 capsules of each formulation were weighed individually
using an electronic balance, average weight was calculated and individual capsule weight was
then compared with average value to find the deviation in weight.
Table: 7.4. Specifications of Percentage weight variation allowed in capsules as per
Indian Pharmacopoeia
S.NO Average weight of capsules
(mg)
Maximum percent
deviation allowed (%)
1. < 130 ±10
2. 130 -324 ±7.5
3. >324 ±5
7.3.2.5. Drug content (Lakshmi Narasaiah .V.,et al.,2011)
The drug content in each capsule was determined by the UV –Spectroscopic
method. An accurately weighed quantity of pellets equivalent to 10 mg of atorvastatin
calcium was transferred to a 100 ml volumetric flask containing 10 ml of methanol and
dissolved. The volume was made up to 100 ml with pH 6.8 phosphate buffer. The solution
was filtered and the absorbance was measured after suitable dilutions by using UV –
Spectrophotometer at 246 nm.
7.3.2.6. Disintegration test (Salam W. Ahjet.,et al., 2009)
Disintegration of pellets was one of the main characteristics for immediate
release pellets. It was performed it in a tablet disintegration apparatus specially designed by
inserting special transparent tubes of certain diameter and length with sieve of 710 mm mesh
size at the bottom of tube. A superdisintegrant was incorporated in all pellet formulations in
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order to fasten the rupture of capsule, which then will dissolve or release the drug faster than
intact capsule.
7.3.3. In-Vitro drug release (Lakshmi Narasaiah .V., et al., 2011)
The release rate of atorvastatin calcium from capsules was determined using USP
Dissolution Testing Apparatus type-II (paddle method; LAB INDIA DISSO 2000,
Hyderabad). The dissolution test was performed using 900 ml of 6.8 phosphate buffer, at 37 ±
0.5°C and 50 rpm. A sample (5 ml) of the solution was withdrawn from the dissolution
apparatus for every 5 min and the samples were replaced with fresh dissolution medium. The
samples were filtered through a 0.45μ membrane filter and diluted to a suitable concentration
with 6.8 phosphate buffer. Absorbance of these solutions was measured at 246 nm using a
Shimadzu-1700 Pharmaspec UV-VISIBLE spectrophotometer. For each formulation, the
experiments were carried out in triplicate. The release data were calculated by using PCP
disso V3 software.
7.3.4. Release kinetics of In-vitro drug release
(Benoy Brata Bhowmik., et al; 2006)
To study the released kinetics of In-vitro drug release, data was applied to kinetic
models such as zero order, first order, Higuchi and Korsmeyer-Peppas.
 Zero order
C= K0t
Where K0
-
is the zero- order rate constant expressed in units of concentration / time.
t- is the time in min .
 First order
LogC = LogC0 –Kt /2.303
Where C0 – is the initial concentration of drug,
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K –is the first order constant
t – is the time in min.
 Higuchi
Qt = Kt1/2
Where Qt - is the amount of the release drug in time t,
K – is the kinetic constant  and
t - is the time in min.
 Korsmeyer Peppas
Mt/M∞ =Kt n
Where Mt – represents amount of the released drug at time t,
M∞ - is the overall amount of the drug  (whole dose) released after 12 hrs,
K – is the diffusional characteristics of drug / polymer system constant,
n – is a diffusional exponent that characterizes the mechanism of release of
drug.
Table: 7.5. Diffusion exponent and solute release mechanism
Overall solute diffusion mechanism
< 0.5 Quasi-Fickian diffusion
0.5 Fickian diffusion
0.5 < n < 1.0 Anomalous (non – Fickian) diffusion
1.0 Case – II  transport
> 1.0 Super case –II transport
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7.4. Stability studies:
(Manavalan R. and Ramasamy S., 2004)
 Introduction
In any rational drug design or evaluation of dosage forms for drugs, the stability of the
active component must be a major criterion in determining their acceptance or rejection.
Stability of a drug can be defined as the time from the date of manufacture and the packaging
of the formulation, until its chemical or biological activity is not less than a predetermined
level of labelled potency and its physical characteristics have not changed appreciably or
deleteriously.
 Objective of the study
The purpose of stability testing is to provide evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental
factors such as temperature, humidity and light, enabling recommended storage conditions,
re-test periods and shelf-lives. Generally, the observation of the rate at which the product
degrades under normal room temperature requires a long time. To avoid this undesirable
delay, the principles of accelerated stability studies are adopted. The International Conference
on Harmonization (ICH) Guidelines titled “Stability testing of New Drug Substances and
Products (QIA) describes the stability test requirements for drug registration application in the
European Union, Japan and the States of America.
ICH specifies the length of study and storage conditions
 Long-Term Testing: 250 C ±20 C at 60% RH ±5% for 12 Months
 Accelerated Testing: 400 C ±20 C at 75% RH ±5% for 6 Months
In present study the selected formulation F4 exposure  up to 3 months stability studies at
long term condition (25
0
C ±2
0
C at 60% RH ±5%) and accelerated condition(40
0
C ±2
0
C at
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75% RH ±5%RH) to find out the effect of aging on hardness, friability, drug content and In-
Vitro drug release.
 Procedure
Stability studies were carried out at long term condition (25
0
C ±2
0
C at 60% RH ±5% ),
accelerated condition (40
0
C ±2
0
C at 75% RH ±5%RH) for the optimized formulation F4. The
capsules were stored at25
0
C ±2
0
C at 60% RH ±5% for long term stability and 40
0
C ±2
0
C at
75% RH ±5%RH for accelerated temperature in closed high density polyethylene bottles for 3
months. The samples were withdrawn after periods of 1 month, 2 month and 3 month. The
samples were analyzed for its Hardness, Percentage Friability, Drug content and In-Vitro drug
release.
RESULTS
AND
DISCUSSION
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8.1. PRE FORMULATION PARAMETERS
8.1.1. Identification of drug
8.1.1.1. Identification by FT-IR spectroscopy
The FT-IR spectrum of atorvastatin calcium was shown in figure 8.1 and the
interpretations of IR frequencies were showed in table 8.1.
Figure: 8.1. FT-IR spectrum of Atorvastatin calcium
 Interpretation of FT-IR Spectrum :
Major functional groups present in atorvastatin calcium showed characteristic peaks in
IR spectrum. Table 8.1 showed peaks observed at different wave numbers and the functional
group associated with these peaks. The major peaks were identical to functional group of
atorvastatin calcium hence; the sample was confirmed as atorvastatin calcium.
8.RESULTS AND DISCUSSION
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Table: 8.1. Characteristic frequencies in FT-IR spectrum of Atorvastatin calcium.
8.1.1.2. Melting point
Melting point values of Atorvastatin calcium sample was found to be in range of
159.20C to 160.70C. The reported melting point for Atorvastatin calcium was 1600C. Hence,
experimental values were in good agreement with official values.
8.1.2. Physicochemical parameters of drug
8.1.2.1. Organoleptic properties
Odour: Pungent odour
Taste: Bitter taste
Colour: White to white off
Nature: Crystalline powder
Wave no.(cm-1) Inference
2972.43 C-H Stretching
2936.75 C-H Stretching
1655.00 C=O Stetching
1594.23 C-H Stretching
1560.48 C=C Stretching
1157.34 C=S Stretching
841.96 C-H Bending
749.38 C-H Bending
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8.1.2.2. Solubility study
Table: 8.2. Solubility profile of Atorvastatin calcium in various solvents.
8.1.2.3. Loss on drying
Table: 8.3. Loss on drying of atorvastatin calcium
*All values are expressed as mean ±S.D.,n=3
The sample passes test for loss on drying as per the limit specified in IP, 2007
(N.M.T. 0.5%).
Name of solvent Parts of solvent required
per solute
Solubility
Distilled water 210 Slightly soluble
Acetonitrile 140 Slightly soluble
Methanol 8 Freely soluble
Ethanol (95%) 1000 Very slightly soluble
Aqueous solution of
pH 4 and below
10,000 Insoluble
pH  7.4 phosphate
buffer
170 Slightly soluble
S. NO. Percentage  LOD Avg. percentage LOD
1 0.3 0.33±0.152
2 0.2
3 0.5
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8.1.3. Analytical methods
8.1.3.1. Determination of λ max
The absorption maximum for atorvastatin calcium in methanol was found to be 246 nm
and absorption maximum was shown in figure 8.2.
Figure: 8.2. λ max observed for Atorvastatin calcium in methanol
8.1.3.2. Preparation of caliberation curve of Atorvastatin calcium in methanol
UV absorption spectrum of Atorvastatin calcium in methanol showed λ max at 246 nm.
Absorbance obtained for various concentrations of Atorvastatin calcium in methanol were
given in table 8.4. The graph of absorbance vs concentration for Atorvastatin calcium was
found to be linear in the concentration range of 2–10 μg /ml. The drug obeys Beer- Lambert’s
law in the range of 2–10 μg /ml.
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Table: 8.4. Data of concentration and absorbance for Atorvastatin calcium in
methanol
S. NO. Concentration (µg/ml) Absorbance
1 0 0.0000
2 2 0.08
3 4 0.156
4 6 0.24
5 8 0.312
6 10 0.4
Figure: 8.3. Caliberation curve of atorvastatin calcium in methanol at 246 nm
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Table: 8.5. Data for caliberation curve Parameters for Atorvastatin Calcium in
methanol.
8.1.3.3.Determination of λ max in 6.8 phosphate buffer
The absorption maximum for Atorvastatin calcium in 6.8 phosphate buffer was
found to be 245 nm and absorption maximum was shown in Figure 8.4
Figure: 8.4. λmax observed for Atorvastatin calcium in 6.8  phosphate buffer
8.1.3.4. Preparation of caliberation curve of atorvastatin calcium in 6.8 phosphate
buffer
UV absorption spectrum of Atorvastatin calcium in 6.8 phosphate buffer  showed λ max
at 246 nm. Absorbance obtained for various concentrations of Atorvastatin calcium in 6.8
phosphate buffer were given in table 8.6. The graph of absorbance vs concentration for
S. NO. Parameters Values
1 Correlation coefficient (r2) 0.9995
2 Slope 0.0397
3 Intercept 0.0006
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Atorvastatin calcium was found to be linear in the concentration range of 2–10 μg /ml. The
drug obeys Beer- Lambert’s law in the range of 2–10 μg /ml.
Table 8.6: Data of concentration and absorbance for atorvastatin calcium in 6.8
phosphate buffer.
Figure: 8.5.Caliberation curve of Atorvastatin calcium in 6.8 phosphate bufferat 245nm
Table: 8.7. Data for caliberation curve parameters for Atorvastatin calcium in 6.8
phosphate buffer.
S.NO Parameters Values
1. Correlation coefficient(r2) 0.999936
2. Slope 0.0070036
3. Intercept 0.000464
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8.1.3.5. Percentage purity of drug
The percentage purity of drug was calculated by using calibration graph method (least
square method).
Table: 8.8. Percentage purity of Atorvastatin calcium
*All the values are expressed as mean± S.D.,n=3
The reported percentage purity for atorvastatin calcium in IP 2007 is 98 to 102%.
8.1.4. Determination of compatibility for drug with superdisintegrants
8.1.4.1. By FT-IR spectroscopy
The FT-IR spectrums of atorvastatin calcium with different superdisintegrants used in
formulation were shown in figure 8.6.
Atorvastatin calcium + SSG
S. No. Percentage purity (%) Avg. percentage
purity (%)
1 99.41
99.52±0.6322
2 98.95
3 100.2
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Atorvastatin calcium + CP
Atorvastatin calcium + CCS
Figure: 8.6. FT-IR spectrum of atorvastatin calcium with SSG, ATC with CP and ATC
with CCS
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Table: 8.9. Major peaks observed in FT-IR spectrum of atorvastatin calcium and ATC
with different superdisintegrants used in formulations.
Wave
No.
(cm-1)
Functional group Peak observed (Yes/No)
ATC ATC+SSG ATC+CP ATC
+CCS
2972.43 C-H Stretching Yes Yes Yes Yes
1560.48 C=C Stretching Yes Yes Yes Yes
1157.34 C=S Stretching Yes Yes Yes Yes
880.54 C-H Bending Yes Yes Yes Yes
841.96 C-H Bending Yes Yes Yes Yes
814.96 C-H Bending Yes Yes Yes Yes
749.38 C-H Bending Yes Yes Yes Yes
According to table 8.9 and figure 8.6 the major peaks observed in drug spectrum were
also observed in spectrums of drug with superdisintegrants; therefore it could indicate that
there was no incompatibility between drug and different superdisintegrants.
8.1.4.2. By DSC thermal analysis
The compatibility and interactions between drugs and superdisintegrants were
checked using DSC thermogram and results obtained were represented in table 8.10 and
figure 8.7
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Atorvastatin calcium
Atorvastatin calcium  + SSG
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Atorvastatin calcium +CP
Atorvastatin calcium +CCS
Figure: 8.7. DSC thermograms of Atorvastatin calcium, ATC with SSG, ATC with CP
and ATC with CCS
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Table 8.10: DSC thermogram parameters
S. No. DSC Thermogram
of ATC
Onset
temperature
(°C)
Peak
temperature
(°C)
Endset
temperature
(°C)
1 ATC  (Drug) 158.2 159.7 160.5
2 ATC + SSG 157.8 159.3 160.8
3 ATC +CP 158.8 159.9 161.1
4 ATC +CCS 157.4 159.1 160.2
According to figure 8.7 and table 8.10, DSC thermogram showed that there was no
major difference in onset temperature, endset temperature and peak temperature when
compared with pure drug’s thermogram. No interaction was found between drug and
superdisintegrants. Therefore it could indicate that there was no incompatibility between drug
and different superdisintegrants.
8.15. Pre formulation studies of powder
Table 8.11: Determination of Bulk density, Tapped density, Carr’s index, Hausner’s
ratio and Angle of repose
S.No. Bulk Density
(gm/ml)
Tapped
density
(gm/ml)
Carr’s
compressibility
index (%)
Hausner’s ratio Angle of
repose ()
1 0.517±0.005 0.653±0.005 20.92±1.509 1.246±0.0057 24˚.93″±0.251
*All the values are expressed as mean±S.D, n=3
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8.1.6. Method of preparation and characterization of pellets
The pellets were prepared by layering of various ingredients mentioned in table 7.1
around the non pareil seeds and used for characterization of various flow properties of pellets.
8.1.6.1. Loose Bulk Density (LBD)
The powder blends of formulations have the bulk density ranged between 0.555±0.00 to
0588±0.01 gm/ml.
8.1.6.2. Tapped bulk density (TBD)
The powder blends of formulations have the tapped bulk density ranged between
0.588±0.01 to 0.666±0.01 gm/ml. These values indicate good packing characteristics and the
powder was not bulky.
Table 8.12: Determination of Physical Characteristics of Atorvastatin calcium pellets
before formulation
*All the values are expressed as mean± S.D., n=3
Formulation Loose bulk
density
(gm/cm3)*
Tapped bulk
density
(gm/cm3)*
Hausner
ratio (HR)*
Carr’s index
(CI)*
F1 0.588±0.01 0.625±0.01 1.062±0.002 5.882±0.003
F2 0.555±0.00 0.588±0.00 1.058±0.004 5.555±0.005
F3 0.588±0.01 0.625±0.02 1.062±0.001 5.882±0.001
F4 0555±0.02 0.588±0.01 1.058±0.003 5.555±0.002
F5 0.588±0.01 0.666±0.01 1.133±0.003 11.764±0.01
F6 0.555±0.01 0.625±0.01 1.125±0.002 11.111±0.008
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8.1.6.3. Carr’s Compressibility Index
The Carr’s index for all the formulations was found to be below 12% indicating that the
powders have a excellent compressibility.
8.1.6.4. Hausner’s Ratio
The hausner’s ratio for all the formulations was found to be <1.25, indicating good flow
properties.
8.2. EVALUATION OF IMMEDIATE RELEASE PELLETS
8.2.1. Appearance
Colour:  White colour.
Shape:  Spherical shape.
8.2.2. Physico chemical characteristics
The physical characteristics of Atorvastatin calcium (F1 to F6)  such as dimension,
hardness, friability, drug content , disintegration time and weight variation were determined
and results of the formulations (F1 to F6) found to be within the limits specified in official
books.
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Table 8.13: Physicochemical characterizations of atorvastatin calcium immediate release
pellets before formulation.
Formulation Dimension* Hardness**
(N)
Friability
(%)*
Drug content
(%w/w)*
F1 0.98±0.01 11±1.52 0.12±0.01 100.1±0.07
F2 0.97±0.01 15±2.00 0.16±0.02 98.85±0.06
F3 1.00±0.02 14±2.51 0.13±0.02 98.35±0.06
F4 1.05±0.02 16±2.00 0.17±0.02 100.05±0.16
F5 0.99±0.03 14±1.52 0.13±0.01 98.72±1.13
F6 1.02±0.02 12±2.03 0.14±0.02 99.89±1.28
All the values are expressed as mean± S.D., *n=3, **n=6.
8.2.2.1. Dimension (size)
Thickness and diameter specifications may be set on an individual product basis. There
were no marked variations in the thickness and diameter of pellets within each formulation
indicating uniform behaviour of pellets. The dimensions of pellets of all formulations were
found to be in the range of 0.97±0.01mm to 1.05±0.02.
8.2.2.2. Pellet Hardness
A difference in pellet hardness reflects difference in pellet density and porosity which in
turn are supposed to result in different release pattern of the drug by affecting the rate of
penetration of dissolution fluid at the surface of the pellet and formation of gel barrier. The
hardness of pellets was found to be in the range of 11±1.52 N to 16±2.00 N. This indicates
good pellet strength.
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8.2.2.3. Percentage Friability
Percentage friability of all the formulations of pellets was found between 0.12± 0.01 %
to 0.17±0.02% .This indicated good handling property of the prepared pellet.
8.2.2.4. Drug content
The content of active ingredients in the formulation was found to be between 98.35±
0.06 % to 100.22±0.16% w/w, which was within the specified limit as per IP, 2007.
8.2.2.5. Disintegration time
The disintegration time of all the formulations was found between 6.3±0.23 min to
7.2±0.2 min, which was within the specified limit as per IP, 2007.
8.2.2.6. Weight Variation
A capsule was designed to contain a specific amount of drug. When the average mass of
the capsule was 300 mg the pharmacopoeia limit for percentage deviation is ±7.5%. The
percentage deviation from average capsule weight for all the capsules were found to be within
the specified limits and hence all formulations complied with the test for weight variation
according to the pharmacopoeia specifications IP. 2007.
Table: 8.14 physicochemical characterizations of Atorvastatin calcium Immediate
release pellets after formulation
Formulations Disintegration time (min)* Weight variation (%) ***
F1 6.8±0.20 ±0.02
F2 6.5±0.15 ±0.03
F3 7.2±0.2 ±0.05
F4 6.3±0.23 ±0.01
F5 7.0±0.12 ±0.09
F6 6.9±0.2 ±0.02
*All the values are expressed as mean ± S.D. *n=3, ***n=20
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8.2.3. In-Vitro Drug released Studies
Table: 8.15. In vitro drug released data for formulation F1
Time
(min)
Dissolution
medium
Absorbance Concentration
(µg/ml)
Amount
(mg)
percentage
drug
released*
0 6.8 pH
phosphate
buffer
0.00 0.00 0.00 0.00
5 0.69 17.510 15.759 52.53±1.21
10 0.94 23.633 21.270 70.9±0.76
15 1.18 29.793 26.814 89.38±1.31
30 1.3 32.676 29.409 98.03±1.13
*All values are expressed as mean ±S.D. n=3.
Figure: 8.8. Plot of In-Vitro drug released profile for formulation F1
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Table: 8.16. In vitro drug released data for formulation F2
Time
(min)
Dissolution
medium
Absorbance Concentration
(µg/ml)
Amount
(mg)
percentage
drug
released*
0 6.8 pH
phosphate
buffer
0 0 0 0
5 0.73 18.34 16.506 55.02±1.24
10 0.99 24.98 22.479 74.93±1.10
15 1.13 28.36 25.530 85.1±1.00
30 1.31 32.92 29.631 98.77±0.93
*All values are expressed as mean ±S.D. n=3.
Figure: 8.9 Plot of In-Vitro drug released profile for formulation F2
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Table 8.17: In vitro drug released data for formulation F3
Time
(hours)
Dissolution
medium
Absorbance Concentration
(µg/ml)
Amount
(mg)
Percentage
drug
released*
0 6.8 pH
phosphate
buffer
0.00 0.00 0.00 0.00
5 0.89 22.55 20.295 67.65±0.44
10 1.05 26.45 23.811 79.37±0.52
15 1.18 29.67 26.703 89.01±0.45
30 1.31 33.1 29.760 99.2±0.41
*All values are expressed as mean ±S.D. n=3.
Figure: 8.10 Plot of In-Vitro drug released profile for formulation F3
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Table: 8.18. In vitro drug released data for formulation F4
Time
(min)
Dissolution
medium
Absorbance Concentration
(µg/ml)
Amount(mg) Percentage
drug
released*
0 6.8 pH
phosphate
buffer
0 0 0 0
5 0.94 24.08 21.669 72.23±0.21
10 1.12 28.17 25.353 84.51±0.40
15 1.21 30.53 27.480 91.6±0.38
30 1.33 33.4 30.060 100.2±0.30
*All values are expressed as mean ±S.D. n=3.
Figure: 8.11. Plot of In-Vitro drug released profile for formulation F4
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Table: 8.19. In vitro drug released data for formulation F5
Time
(min)
Dissolution
medium
Absorbance Concentration
(µg/ml)
Amount
(mg)
percentage
drug
released*
0 6.8 pH
phosphate
buffer
0 0 0.00 0.00
5 0.92 23.21 20.886 69.62±0.19
10 1.11 27.93 25.134 83.78±0.24
15 1.2 30.2 27.183 90.61±0.35
30 1.32 33.17 29.853 99.51±0.27
*All values are expressed as mean ±S.D. n=3.
Figure: 8.12. Plot of In-Vitro drug released profile for formulation F5
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Table: 8.20. In vitro drug released data for formulation F6
Time
(min)
Dissolution
medium
Absorbance Concentration(µg/ml) Amount
(mg)
Percentage
drug
released*
0 6.8 pH
phosphate
buffer
0.00 0.00 0.00 0.00
5 0.86 21.73 19.554 65.18±0.20
10 0.96 24.22 21.801 72.67±0.34
15 1.16 29.19 26.271 87.57±0.28
30 1.32 33.25 29.925 99.75±0.17
*All values are expressed as mean ±S.D. n=3.
Figure 8.13: Plot of In-Vitro drug released profile for formulation F6
The drug released data of dissolution studies of formulations F1-F2 containing
SSG shown in table 8.15 & 8.16. The drug released from formulations F1-F2 containing SSG
at two concentration levels of 4%, 8% were found to be 98.03±1.13% and 98.77±0.93%
respectively.
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The drug released from formulation F3-F4 containing Crospovidone at two
concentration levels of 4% and 8%  were found to be 99.2±0.41%and 100.2±0.30%
respectively (Table 8.17 & 8.18). While the drug released from formulation F5-F6 containing
croscarmellose sodium at two concentration levels of 4% and 8% were found to be
99.51±0.27%, 99.75±0.17 % respectively (Table 8.19& 8.20).
Table: 8.21. In vitro drug released data for Innovator drug
Time
(min)
Dissolution
medium
Absorbance Concentration
(µg/ml)
Amount (mg) % Drug
released*
0
6.8 phosphate
buffer
0.00 0.00 0.00 0.00
5 0.17 23.58 21.228 70.76±0.17
10 0.20 27.96 25.167 83.89±0.02
15 0.22 30.81 27.726 92.42±0.25
30 0.234 33.43 30.093 100.31±
0.43
*All values are expressed as mean ± S.D. n=3.
Figure: 8.14 Plot of In vitro drug released profile for Innovator drug.
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Table: 8.22. Comprehensive in vitro drug released data for formulations F1 – F6 and
Innovator drug.
Time
(min)
Formulations* Innovator
drug*F1 F2 F3 F4 F5 F6
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
5 52.53±1.21 55.02±1.24 67.65±0.44 72.23±0.21 69.62±0.19 65.18±0.2 70.76±0.17
10 70.9±0.76 74.93±1.10 79.37±0.52 84.51±0.40 83.78±0.24 72.67±0.34 83.89±0.02
15 89.38±1.31 85.1±1.00 89.01±0.45 91.6±0.38 90.61±0.35 87.57±0.28 92.42±0.25
30 98.03±1.13 98.77±0.93 99.2±0.41 100.2±0.30 99.51±0.27 99.75±0.17 100.31±0.4
*All values are expressed as mean ± S.D. n=3.
Figure: 8.15. Plot of in vitro drug released profile for formulations F1 to F6 and
Innovator drug.
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Table: 8.23. Time of drug released values of t25, t50 and t90 for pellet formulations
F1 to F6 and Innovator drug
Formulations Time of % drug released (min)
25% (t25) 50%(t50) 90%(t90)
F1 2.4 4.8 16.6
F2 2.2 4.6 20
F3 1.8 3.85 17
F4 1.8 3.6 13.6
F5 1.8 3.6 14
F6 2.0 3.8 17.6
Innovator drug 1.85 3.6 13.6
Figure: 8.16. Histogram for time of drug released values of t25, t50 and t90 of formulations
F1 to F6 and Innovator drug.
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Figure: 8.17 Histogram for time of drug released values of t25, t50 and t90 of optimized
formulation (F4)
The comparative effect of three different super disintegrants on the released profile of
atorvastatin calcium  from the immediate release formulations in terms of percentage drug
release was found that crospovidone 8% release the drug quickly than those containing SSG
and CCS. It was observed that formulations having low values of mean dissolution time
(MDT) indicated the faster released of the drug than the other formulations.
The release profiles of all the batches were fitted to different models. But the
superiority of other model was however statistically insignificant with Korsmeyer Peppas
model as shown by the goodness of fit test (t-test). Thus it may be concluded that the drug
release from Atorvastatin calcium immediate release pellets was best explained by Korsmeyer
Peppas model.
By graphical method ,by taking time on x –axis and drug release on y -axis  were used
to find out time required to release 25% drug (t25), time required to release 50% drug (t50) and
time required to release 90% drug (t90) drug for each batch and Innovator drug.
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The result of t25, t50 and t90 are shown in table 8.23 and figure 8.16, according to the
time of drug release values of t25, t50 and t90 the formulation F4 (8%)was selected as the best
formulation of crospovidone respectively. The drug release profile of selected formulations
was shown in figure 8.17; it shows that the formulation F4 showed the immediate drug release
profile for 30 min as compared to formulation F3.
From the above study it was concluded that the formulation F4 showed the immediate
drug release profile with immediate onset of action, less disintegration time and less time of
drug release as compared with the all batches for these reason the formulation F4 was
considered as the best formulation among all the six formulations of this series. Hence the
formulation F4 was selected for further stability study.
8.2.4. Release Kinetics of In-vitro Drug Release
The kinetics of in-vitro drug released was determined by applying the drug release
data to various kinetic models such as zero order, first order, Higuchi and Korsmeyer –
Peppas. The results were represented in table 8.24 and shown in figures 8.18 to 8.23.
Table: 8.24 Release kinetics of in-vitro drug release
Formulation Zero order First order Higuchi Peppas Best fit
model
R2 R2 R2 R2
F1 0.6836 0.6742 0.9690 0.996 Peppas
F2 0.6557 0.6671 0.9678 0.998 Peppas
F3 0.4667 0.4629 0.9291 0.997 Peppas
F4 0.3519 0.3742 0.9077 0.999 Peppas
F5 0.3951 0.3609 0.9154 0.998 Peppas
F6 0.5663 0.5581 0.9481 0.997 Peppas
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Figure: 8.18 Best fit model (Korsmeyer- Peppas) of formulation F1
Figure: 8.19 Best fit model (Korsmeyer – Peppas) of formulation F2
Figure: 8.20 Best fit model (Korsmeyer- Peppas) of formulation F3
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Figure: 8.21 Best fit model  (Korsmeyer-Peppas) of formulation F4
Figure: 8.22. Best fit model (Korsmeyer-Peppas) of formulation F5
Figure: 8.23. Best fit model (Korsmeyer-Peppas) of formulation F6
R² = 0.999
0
0.5
1
1.5
2
2.5
3
0 0.5 1 1.5 2
log
 % 
dru
g r
ele
ase
d
log time (min)
Korsmeyer-Peppas plot
log % drug released
Linear (log % drug
released)
R² = 0.998
0
0.5
1
1.5
2
2.5
3
0 0.5 1 1.5 2
log
 % 
dru
g r
ele
ase
d
log time (min)
Korsmeyer-Peppas plot
log % drug released
Linear (log % drug
released)
R² = 0.997
0
0.5
1
1.5
2
2.5
3
0 0.5 1 1.5 2
log
 % 
dru
g r
ele
ase
d
log time (min)
Korsmeyer-Peppas plot
log % drug released
Linear (log % drug
released)
Atorvastatin Calcium Immediate Release Pellets Results and Discussion
Page 131
Adhiparasakthi college of  Pharmacy, Melmaruvathur.
8.3. STABILITY STUDY OF SELECTED FORMULATION
8.3.1. Short term stability conditions for formulation F4 at room temperature.
After exposing to short term stability conditions the formulation was analyzed for
various evaluation parameters results were shown in table 8.25.
Table: 8.25. Stability studies of optimized formulation F4 –Room temperature
S.NO Parameters Initial At  25˚C±2˚C at 60%RH±5%
1st month 2nd month 3rd month
1 Description complies complies Complies Complies
2
Average weight(mg) 300 300 300 300
3 Average hardness(N)** 16±2.00 16±2.00 15.5±1.52 15.1±1.5
4 Friability (%)* 0.17±0.02 0.17±0.02 0.18±0.03 0.22±0.01
5
Drug content(%w/w)* 100.05±0.16 100.03±0.07 100±0.04 99.96±0.06
6.
In-vitro drug released (%)* 100.2±0.30 100±0.25 99.8±0.3 99.76±0.15
*All the values are expressed as mean± S.D., *n=3, **n=6
8.3.2. Short term stability conditions for formulation F4 at Accelerated temperature
After exposing to accelerated stability conditions the formulation was analyzed for
various evaluation parameters results were shown in table 8.26.
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Table: 8.26 Stability studies of optimized formulation F4 - Accelerated condition
SNO Parameters Initial At  At 40˚C±2˚C  at  75%±5%RH
1st month 2nd month 3rd month
1 Description complies Complies complies Complies
2
Average weight(mg) 300 300 300 300
3 Average hardness(N)** 16±2.00 15.5±0.25 15±0.3 14.9±0.26
4 Friability (%)* 0.17±0.02 0.18±0.01 0.19±0.02 0.21±0.03
5
Drug content(%w/w)* 100.05±0.16 99.99±0.5 99.97±1.35 99.95±0.2
6.
In- vitro drug released (%)* 100.2±0.30 99.7±0.32 99.4±0.2 99.23±0.15
*All the values are expressed as mean± S.D., *n=3, ** n=6
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Figure: 8.24. Histogram for Percentage drug released of before and after stability
studies for optimized formulation F4.
Figure: 8.25. Histogram for Percentage drug content of before and after stability
studies for optimized formulation F4.
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No major difference was found between evaluated parameters before and after
stability studies and all are in acceptable limits. The pellets showed satisfactory physical
stability at 25º C at 60% RH and 40 º C at 75 % RH.
SUMMARY
AND
CONCLUSION
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9. SUMMARY AND CONCLUSION
 The atorvastatin calcium was widely used in the anti lipedimic drug. It also
stabilizes plaque and prevents inflammatory and other mechanisms. This research work
mainly focused on therapeutic effect of the drug to increased bioavailability. The reported
bioavailability of atorvastatin calcium was only 14% and it was highly soluble in acidic pH
and absorbed in upper part of GIT. While forming the multi particulate drug delivery system
in the form of immediate release pellets leads to an increased in the surface area to improved
solubility and dissolution rate and significantly increased the bioavailability of drug.
 The drug fall under the class II (BCS classification; i.e. Low soluble: high
permeability) from the ethical and pharmacokinetic view, dissolution test must be performed.
Hence the prepared atorvastatin calcium pellets must comply with dissolution test as per
innovator drug (LIPITOR).
 The identification of drug was carried out by FT-IR spectroscopy and melting
point. The physicochemical parameters such as appearance, solubility study and loss on
drying were performed by suitable methods. The analytical profile of drug was evaluated for
determination of absorption maximum, development of standard curve and percentage purity
of drug. Compatibility of drug and excipient mixture was done by performing FT-IR and DSC
study. It was concluded that there was no interaction between the drug and superdisintegrants
as the principle peaks of the drug were found unaltered in the FT-IR spectra and DSC
thermogram of drug superdisintegrants physical mixture. The pellets was prepared by coating
the drug and superdisintegrants in conventional pan coater until minimum weight was gained
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and sieved through 40 #size to obtained uniform size  and evaluated for bulk density, tapped
density, Carr’s index, Hausner’s ratio and angle of repose.
 The present work was proposed to prepare pellets loaded with Atorvastatin
calcium to achieve better bioavailability with low dose of the drug at the site, decreased the
risk of adverse side effects based on in- vitro released study. Atorvastatin calcium pellets were
prepared by drug layering method for all the formulations F1 to F6. Formulations were
prepared composed of HPMC E15, polyvinyl pyrolidone as a binder, SSG (4% & 8%), CP
(4% & 8%), and CCS (4% & 8%) as coating material, Isopropyl alcohol as a vehicle and talc
as a glidant. The all formulations were evaluated for the appearance, dimension, hardness,
percentage friability, disintegration time, drug content and in- vitro drug released. Also the all
formulations were compared with one innovator product and results of products were
compared. The formulation F4 was best one compared to other formulations and Innovator
product. On the performance with respected to disintegration time, and the in- vitro released
characteristics, the formulation F4 was selected as the best formulation. This formulation
showed an immediate released rate throughout its released period. Further the selected
formulation F4 was subjected to short term stability study at Room temperature (25±2˚C at RH
60% ± 5%) and Accelerated temperature (40±2˚C at RH 75% ±5%).
 According to stability study it was found that there was no significant change in
hardness, drug content, percentage friability and in-vitro drug released of optimized
formulation F4.
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It may be concluded that the Immediate released pellets of Atorvastatin calcium
was feasible and may be manufactured with reproducible characteristics with the aid of
crosspovidone (8%) as a superdisintegrant. However it needs further in depth animal studies
on suitable animal models with statistical clinical data for a dependable and successful
pharmaceutical marketing formulation.
FUTURE
PROSPECTUS
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In the field of Multi particulate drug delivery system, there are many obstacles
that need to be over come in order to able to claim true pellet formulation. Considering the
advantages for improved delivery of drugs further clinical studies are needed to access the
utility of this system for patients suffering from hypercholesterolemia.
This formulation holds promise for further systems. Animal studies,
toxicological studies and in- vitro-in- vivo correlation (IV-IVC) will serve as a modelling the
human organism and of gaining a better understanding of drug abortion and its dependence on
in -vitro release process.
Once the technology is fully accepted, these systems will probably increase with new
pipeline drugs that need enhancement to their bioavailability.
10.FUTURE PROSPECTUS
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